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Patients with metastatic or inoperable kidney cancer with positive biomarkers of 
vascular endothelial growth factor (VEGF) driven angiogenesis might have improved 
clinical benefit from treatment with an anti-VEGF-receptor kinase inhibitor. The 
primary goal in this study was to identify predictive markers of response in first line 
treatment with sunitinib against kidney cancer, and the secondary goal was to 
estimate response, proportion of patients with stable disease on treatment, time to 
progression, and survival.  
 
Material and methods: 
Forty-six patients with metastatic clear cell renal cell carcinoma (ccRCC) were 
enrolled in a prospective single-arm study of predictive markers for sunitinib 
response.  
In paper I, response rates according to RECIST v.1.1. were used as primary end-
point. Secondary objectives were to evaluate prognostic value of candidate markers 
with regard to progression free survival (PFS) and overall survival (OS). In addition, 
toxicity rates and quality of life were reported.  
In paper II, we investigated the predictive value of immunohistochemical 
biomarkers associated with angiogenesis and systemic inflammation in metastatic 
ccRCC. Forty-six patients with metastatic or non-resectable ccRCC treated with 
sunitinib were included. Metastatic and/or primary tumor tissue were stained by 
immunohistochemistry for selected markers related to angiogenesis (VEGF-A, 
VEGFR2, PDGFRβ, HSP27) and immune responses (IL6, IL6Rα, JAG1). The 
predictive potential of the candidate markers was assessed by correlations with 
response rates. In addition, PFS and OS were analyzed.  
In paper III, full blood samples were collected at baseline before start of sunitinib 
and after every second cycle of treatment during the study time. Markers of immune 
response (pIL6, pIL6Rα and pIL6ST) at baseline and week 12 were analyzed by 
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ELISA. The predictive potential of the candidate markers was assessed by correlation 
with response rates. In addition, PFS and OS were analyzed. 
 
Results:  
Paper I: Median PFS and OS were 9.1 months and 15.0 months, respectively. Of 38 
patients evaluable for response, 1 patient had complete response (CR), 7 had partial 
response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). 
Normal CRP at baseline was significantly associated with objective response (CR + 
PR) (Fisher’s exact test, p = 0.01). Normal CRP was also significantly associated 
with improved PFS and OS (Log rank, p = 0.05 and < 0.01, respectively). Early 
hypertension, neutrophil-to-lymphocyte ratio (NLR) and IMDC risk score were not 
significantly associated with response rates or survival. 
Paper II: Low tumor cell expression of IL6Rα was significantly associated with 
improved response to sunitinib (Fisher’s exact test, p = 0.03), but not with PFS or OS. 
Median/high expression of IL6Rα showed significant association with median/high 
expression of VEGF-A and HSP27. Furthermore, low tumor cell expression of IL6 
was significantly associated with improved PFS, but not OS or response rates. High 
expression of IL6 was significantly associated with high expression of JAG1, VEGF-
A, VEGFR2 and PDGFRβ. 
Paper III: Low pIL6 at baseline was significantly associated with improved response 
to sunitinib (Fisher's exact test, p < 0.01). Furthermore, low pIL6 at baseline was 
significantly associated with improved PFS (Log rank, p = 0.04). In addition, patients 
with a decrease in concentration of pIL6Rα between baseline and week 12 showed 
significantly improved PFS (Log rank, p = 0.04) and patients with high pIL6ST at 
baseline showed significantly improved OS (Log rank, p = 0.03). 
 
Conclusion: 
Baseline CRP was a significant predictive factor of sunitinib response and a 
prognostic factor of survival. Baseline CRP might be a useful biomarker in the 
treatment planning of metastatic ccRCC. Loss of tumor cell expression of IL6Rα in 
patients with metastatic ccRCC patients treated with sunitinib predicts improved 
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treatment response. Low pIL6 at baseline in metastatic ccRCC patients treated with 
sunitinib predicts improved treatment response. Both might represent candidate 
predictive markers. Because of the relatively small sample size, the results need 
validation in larger studies. 
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This thesis focuses on predictive biomarkers for treatment of metastatic clear cell 
renal cell carcinoma (ccRCC) with sunitinib. 
1.1 Epidemiology of renal cell carcinoma 
Kidney cancer represent three to four percent of malignant tumors among adults in 
Norway 1. Renal cell carcinoma (RCC) arise from cells in the kidney and is a 
heterogeneous group of sporadic or hereditary cancers 2. According to the Cancer 
Registry of Norway, during the last decade men have a higher and steeper increase of 
incidence than women 1. The mortality rate has been moderately decreasing and 
survival rates have been increasing (Figure 1) 1. Worldwide in 2012, kidney cancer 
was the ninth most common cancer in men and the 14th most common cancer in 
women. It was the 16th most common cause of death from cancer in 2012 2. It is more 
frequent in countries with high and very high levels of human development 2. 
 
Figure 1. Kidney excluding renal pelvis (ICD-10 C64). Printed with permission by 
The Norwegian Cancer Registry 1.  
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1.2 Etiology and risk factors 
 Risk factors 
Increasing age and higher incidence among men versus women at a ratio 1.5:1 are 
risk factors of RCC 3.  
 
Smoking and obesity are the most common risk factors related to RCC 2,4,5. The link 
between smoking and RCC is thought to be through induction of hypoxia over time 6. 
There is a strong dose-dependent increase in risk associated with numbers of 
cigarettes smoked per day 2. The risk was reduced among persons that quit smoking 
more than 10 years ago versus those less than 10 years 5.  
 
Obesity increases the risk of RCC. In a meta-analysis the relative risk estimate was 
1.07 (95% CI 1.05–1.09) per unit of increase in BMI 4. RCC and obesity are 
interconnected via inflammation, tissue hypoxia, lipid peroxidation, increased 
production of insulin-like- and other growth factors 7. Obesity may be considered a 
low-grade chronic infection through activation of acute phase proteins and systemic 
inflammatory response proteins 7. The majority of inflammatory cytokines in obesity 
are from infiltrating macrophages in adipose tissue. Of these, interleukin 6 (IL6) is 
one of the most important 7.  
 
Hypertension increased the risk of RCC among men and women in a cohort of 
156,774 subjects, where increasing blood pressure was correlated to increased hazard 
ratio 8. In the Norwegian HUNT study, the relative risk of RCC was increased in 
women with hypertension, but not among men 9.  
 
Kidney disease as acquired cystic kidney disease, in end-stage kidney disease, has a 
six-fold higher incidence of RCC compared to the general population 10. Kidney 
transplantation and immunosuppression increase the risk of RCC in the non-
transplanted kidney and this might argue for a role of the immune system in 
repressing kidney cancer development 11.  
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Substances like asbestos, trichloroethylene, cadmium, lead and chronic exposure to 
arsenic in drinking water are linked to the risk of RCC 12-19, but more robust studies 
are needed to confirm this 3. Moreover, modern diets with high protein and low fat 
have been linked to increased risk of RCC 10.  
 
Physical activity may reduce the risk by reducing obesity, blood pressure, insulin 
resistance and lipid peroxidation, and it was shown to reduce risk of RCC in a meta-
analysis (relative risk (RR) 0.88, 95% CI 0.79 - 0.97) 3,20.  
 
 Genetic risk factors 
Only around 2% of RCC is hereditary; still the hereditary syndromes have given 
insight to mechanisms found in sporadic tumors 21. Young age (under 40 years of 
age), bilateral or multifocal renal tumor and family history of renal cancer suggest an 
inherited predisposition 22. Mutations in the von-Hippel-Lindau (VHL) gene are 
important in hereditary RCC 21. The gene is located on chromosome 3 (3p25-p26) 
and was first identified and cloned in 1993 21. Inactivation of the VHL gene appears 
in 60-80 % of the sporadic ccRCC 23,24. The two hit tumor suppressor gene, VHL, has 
one allele inactivated by mutation or promoter methylation and the other lost because 
of a large deletion 25. Loss of the VHL-gene leads to high levels of hypoxia-inducible 
factor 1 α (HIF1α), a transcription factor for a number of stress response proteins 26. 
In turn, this leads to upregulation of vascular endothelial growth factors (VEGF), 
which induces angiogenesis and thus represents the rationale behind sunitinib 
treatment 27.  
 
In ccRCC, tumor suppressor genes Polybromo 1 (PBRM1), BRCA1 associated 
protein-1 (BAP1) and SET domain containing protein 2 (SETD2) at 3p have emerged 
as major cancer genes, which regulate different gene expression programs 2,28. 
PBRM1, BAP1, SETD2 and VHL are all on chromosome 3p and are lost in 
approximately 90% of sporadic RCCs 28. In patients treated with VEGF targeted 
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therapy, those with mutation of PBRM1 had longer time to treatment failure 
compared those with wild type (Log rank, median 12.0 months versus 6.9 months, 
p = 0.01) 29. Patients with metastatic ccRCC with mutations in PBRM1 had increased 
clinical benefit to immune checkpoint therapy 30. These patients also had increased 
expression of hypoxia and IL-6–JAK-STAT3 gene sets in the PBRM1-LOF tumors 
30.  
 
For more about other hereditary RCCs please refer to the review by Kallinikas et al 
31. 
 
1.3 Classification of RCC 
 TNM classification 
The staging system in RCC is based on the TNM classification as an anatomical 
prognostic marker to give information about survival probability 32,33. The TNM 
staging system describes tumor size, and define the extent of local disease and 
presence of metastases. The recent TNM stage system is from 2017 (8th edition) 33.  
 Histopathological classification 
The consensus meetings in Heidelberg and Rochester used for the first time genetic 
information to classify RCC in addition to histologic appearance and architecture 34. 
The agreements from these meetings were leading up to the World Health 
Organization (WHO) classification in 2004 35. The latest version from 2016 includes 
more than 50 variants of renal neoplasms 36. The main groups are ccRCC (c. 70%), 
papillary RCC (type I and II) (c. 10-15%), chromophobe RCC (c. 5%) and collecting 
duct carcinoma (< 1%) 2. Others variants are medullary carcinoma and other rare 





A  B  C  
 Figure 2. A: Clear cell RCC, B: Papillary RCC type I, C: Chromophobe RCC.  
Photos adopted with permission from oncolex.no (http://oncolex.no/Nyre/Bakgrunn/Histologi).  
Clear cell RCC 
Clear cell RCC (ccRCC) origins from the epithelium of the renal tubules 36. 
Macroscopically, the cut surface is golden-yellow, often with hemorrhage and 
necrosis 38. ccRCCs are defined as a morphologically heterogeneous malignant 
neoplasms composed of cells with clear and/or eosinophilic cytoplasm, and they are 
typically associated with a vascular network and inactivation of the VHL gene either 
with mutation or methylation in over 80% and upregulation of HIF1α 28,39. Loss of 
the chromosome 3p and mutation of the VHL gene at chromosome 3p25 are 
frequently found 28. Other tumor suppressor genes as PBRM1, BAP1 and SETD2 are 
also frequently deleted in ccRCC 28,38. 
Papillary RCC 
Papillary RCC (pRCC) is the second most commonly encountered morphotype of 
RCC 38. It is divided into two subtypes, pRCC type I and type II 36. pRCC type I is 
associated with activating germline mutations of MET and pRCC type II is associated 
with activation of the NF-E2-related factor 2-antioxidant responsive element (NRF2-
ARE) pathway with at least three subtypes 38. Macroscopically, pRCC is typically 
well circumscribed with a fibrous capsule, with a yellow or brown color 39. Foamy 
macrophages and cholesterol crystals are characteristic in the fibrovasculare core of 
the papillo-tubular structure 39. Hemorrhage and necrosis are often seen 39. 
Microscopically, in pRCC type I, cancer cells are small, and they have scanty 
basophilic or pale cytoplasm and low-grade nuclei without nuclear pseudo-
stratification 39. pRCC type II is composed of cancer cells having abundant 
eosinophilic cytoplasm and high-grade nuclei with pseudo-stratification 39.  
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Chromophobe RCC 
Chromophobe RCC (chRCC) is macroscopically a pale tan, homogenous and though, 
well-demarcated mass without a capsule 38. Microscopically, it has prominent cell 
membranes, wrinkled nuclei with perinuclear halos, and pale to eosinophilic 
cytoplasm, and it comprises about 5 % of all renal tumors 39. Loss of chromosomes 
are typical genetic changes 35,40.  
 
 Histopathological grading of RCC 
Histologic subtyping is an important prognostic marker in RCC 41. ccRCC subtype 
has a worse prognosis compared to pRCC and chRCC 41,42.  
 
The Fuhrman grading system has been used the last four decades for nuclear grading 
43. The system scores the assessment of nuclear size, nuclear irregularity and 
nucleolar prominence to grade tumors into four groups 43. A weakness with the 
Fuhrman grading has been the use of simultaneous assessments of the three 
parameters 44. It is difficult to evaluate tumors where two or three of the nuclear 
parameters appear to contradict each other 44. In addition, there may be poor 
inter/intra-observer reproducibility and failure to discriminate outcome adequately 45.  
 
The Fuhrman grading system is still in use, but because of its weaknesses, the 
International Society of Urological Pathology (ISUP) suggested a new method of 
grading 44. In the ISUP system, grade 1-3 defines tumor classes based on nucleolar 
prominence and grade 4 on the presence of pronounced nuclear polymorphism, tumor 
giant cells and/or rhabdoid and/or sarcomatoid differentiation 36. Sarcomatoid 
features represent worse prognosis and it represent an ISUP score of grade 4 44. 
Microscopic appearances of coagulative necrosis predict worse prognosis for ccRCC 
and chRCC 44.  
 
The ISUP system is recommended and validated for ccRCC and pRCC 44,45. The 
Fuhrman and ISUP grading are not recommended for chRCC 36. 
 20
1.4 Diagnostics in RCC 
A multidisciplinary team is mandatory in the diagnostic investigation, before either 
surgery and/or systemic treatment. The clinical presentation of the patient’s 
symptoms, medical history and performance status gives important information. 
Because of increased incidental findings of RCC on CT scans, the classic triad of 
pain, hematuria and palpable flank mass is less common today 46,47. RCC can present 
with symptoms from local tumor growth, hematuria because of bleeding, 
paraneoplastic manifestations or metastatic disease 38. RCC occasionally presents 
with paraneoplastic manifestations like hypercalcemia, production of an 
adrenocorticotrophic hormone, hepatic dysfunction, polycythemia, fever, amyloidosis 
and weight loss 47. Other presentations could be hypertension, night sweats, malaise 
and in men varicocele, usually left sided, because of obstruction of the testicular vein 
(2% of males) 48. 
 
RCC can develop into an advanced stage without warning signs or abnormal blood 
test. This makes it difficult to detect RCC at an early stage. One-third of all patients 
are diagnosed with metastases and over 20% of patients undergoing nephrectomy 
with curative intention will develop metastases during follow-up 49. Distant 
metastases occur most often in the lungs, lymph nodes, liver, bone, and the brain 49,50. 
Metastatic RCC can present with several different symptoms. Lung metastases can 
present with coughing or dyspnea, brain metastases may present with confusion, 
dizziness or epileptic seizure and bone metastasis with pain or pathological fracture 
36.  
 
In addition to clinical presentation, a physical examination and laboratory findings 
will give information about the patient can benefit from surgery and/or systemic 
treatment. It is also necessary to evaluate performance status, any comorbidity and 
risk of complications, especially if surgery is considered.  
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Mandatory in the diagnostic work up is imaging. CT-scan is the preferred imaging 
method in RCC diagnostic and staging 38. In patients with reduced renal function 
MRI is preferable to preserve kidney function, because MRI give the opportunity to a 
non-contrast diagnostic method 38.  
 
A tissue biopsy is important to get the correct diagnosis and to decide treatment or no 
treatment 38. Biopsies may show benign tumors in small renal masses and in that way 
support the use of active surveillance. It may also support use of a non-surgical 
method as ablative treatment or use of systemic targeted treatment 38. At least two 
core biopsies should be used to ensure proper quality. 
 
1.5 Tumor biology 
The path from normal cells to cancer cells and metastatic cancer cells follow multiple 
steps from accumulation of genetic alterations and epigenetic modifications, like 
activation of oncogenes and inactivation of tumor suppressor genes. Hanahan and 
Weinberg presented their principles of cancer tumor biology, the hallmarks of cancer 
51,52. The first six core hallmarks established in 2000 were; sustaining proliferative 
signaling, evading growth suppressors, activating invasion and metastases, enabling 
replicative immortality, inducing angiogenesis and resisting cell death 51. And in 
2011, deregulation of cellular energetics and avoidance of immune destruction were 
added and also two enabling characteristics of neoplasia; tumor-promoting 
inflammation and genome instability and mutation 52.  
 
 Cell cycle regulation 
To maintain tissue homeostasis and avoid neoplastic growth the proliferative activity 
of cells 53, cyclin proteins and the associated cyclin-dependent kinases regulates 
checkpoint controls that monitor the four phases of the cell cycle 54. These are the 
first gap phase (G1), the synthetic phase (S), the second gap phase (G2) and mitosis 
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(M)) 54. In the non-proliferating G0 state, the cells need external growth factors to 
enter the cell cycle and the G1 phase 54.  
 
 Hypoxia, angiogenesis and VEGF  
Angiogenesis is defined as sprouting of new vessels from pre-existing vessels 55,56. 
Tumors over 1-2 mm2 are dependent on neovascularization to continue growth 57. 
Folkman predicted a tumor-angiogenesis factor (TAF) responsible for tumor 
angiogenesis 57. A decade later vascular permeability factor (VPF) was purified 58, 
and later renamed to VEGF 59. Angiogenesis is involved in several physiological 
processes and is very important for the survival and proliferation of cancer cells, 
tumor growth and spreading 60. 
 
The most important physiologic driver of angiogenesis is hypoxia 60. Hypoxia is a 
result of imbalance between oxygen supply and consumption in tumors 60. Cancer 
cells surviving in a hypoxic environment are more resistant to chemotherapy and 
radiotherapy 60. These features are beneficial for cancer cells and reduce overall 
survival for the host 61.  
 
The VHL tumor suppressor gene is lost or mutated in 60-90% in sporadic cases and is 
a major contributor to development of RCC 23. Loss of VHL leads to a chronic stress 
response state in the cells trough high levels of HIF1α, a transcription factor for a 
number of stress response proteins, including increased production of VEGF, that is 
triggered as a hypoxia response because of HIF1α 62. Other regulators of VEGF are 
epidermal growth factors (EGF), transforming growth factor (PDGF), insulin-like 
growth factor 1 (ILGF-1), and fibroblast growth factor (FGF) 62.  
 
VEGF is produced by hypoxic tumor cells, endothelial cells and tumor associated 
macrophages 63. VEGF consists of different variants. The VEGF family includes 
VEGF A, B, C, D and placental growth factor (PIGF) 60. VEGF is the most important 
factor that induce angiogenesis 60. VEGF has a proliferative effect on endothelial 
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cells, which start growing because of VEGF, increasing survival and decreasing the 
apoptotic rate 60. Furthermore, it enhances vascular permeability, which in turn is 
related to extravasation and migration of cells from and into circulation 60.  
 
VEGF is the most important mediator of tumor-associated angiogenesis in RCC, and 
VEGF receptor 2 (VEGFR2) is the main target of sunitinib. Some reports suggest a 
role of systemic inflammation in development and progression of RCC 64-66.  
 
Through its major downstream target STAT3 several tumor promoting pathways are 
activated, including HIF1α and increased VEGF activity 67. As a response to cellular 
stress, IL6 activation of the transcription factor STAT3 drives angiogenesis by 
inducing expression of VEGF and fibroblast growth factor (bFGF) by tumor cells, 
and thereby supports vascularization required for tumor growth and metastasis 68,69. 
 
 Inflammation 
Inflammation is a result of tissue trauma when inflammatory cells infiltrate in to the 
tissue and production of cytokines and growth factors regulates cellular proliferation 
70. Similarly, cancer promotes development of an inflammatory  
microenvironment in and around tumors and as well systemic inflammation 71. 
Rudolf Virchow observed lymphoreticular infiltration in cancer tissue and suggested 
a link between inflammation and cancer 72.  
 
Tumor inflammation is important in both tumor promoting and anti-cancer processes. 
Cancer cells use the immune system in development of local tumor growth and 
metastasis. Cancer can avoid and suppress the immune response. Usually, the innate 
and adaptive immune system recognizes and eliminates tumor cells 73. The cancer 
cells can stay in dormancy over many years, where tumor cells and the host immune 
system stay in an equilibrium until tumor cells escape from the immune system and 
starts to grow progressively 73,74.  
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Cancer-related inflammation involves the infiltration of tumor associated 
macrophages (TAMs), white blood cells and inflammatory cytokines, like tumor 
necrosis factor (TNF), interleukin 1 (IL1) and IL6, and chemokines (CCL2 and 
CXCL8), which facilitate tissue remodeling and angiogenesis 75. The production of 
different inflammatory cytokines, chemokines, and growth factors by RCC cells and 
tumor stromal cells stimulates the activation, expansion, and trafficking of various 
immune cells into the tumor where they can promote tumor progression by enhancing 
angiogenesis and initiate T cell immune suppression 76,77. 
 
IL-6 is an important tumor-promoting protein associated with stress responses, 
inflammation and angiogenesis 67. Through its major downstream target STAT3 
several tumor promoting pathways are activated, including HIF1α and VEGF 67. 
Moreover, IL6 have direct stimulating effect on endothelial cells, and has been 
implicated in resistance to anti-VEGF therapy 78. 
 
C-reactive protein (CRP) is an acute-phase protein that increases rapidly following 
IL6 secretion by macrophages and T cells following infection, inflammation and 
cancer 79. 
 
Along with a stimulating effect on tumor associated angiogenesis, VEGF also plays 
an important role as a suppressor of the local immune response during wound healing 
as well as in tumors by inducing accumulation of immature dendritic cells, myeloid-
derived suppressor cells (MDSC), regulatory T cells, and VEGF inhibits the 
migration of T lymphocytes to the tumor 80.  
 
The neutrophil-to-lymphocyte ratio (NLR) is also a marker of systemic inflammation 
in cancer patients and was found in retrospective RCC studies to add prognostic and 
predictive information 81,82. Like CRP, NLR is readily available in standard blood 
samples in a regular clinical setting. 
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 Activating invasion and metastases 
Cancer cells have the ability to activate invasion and disseminate to distant locations. 
Metastases from solid tumors are related to over 90% of cancer-associated deaths 54. 
The first step of the metastatic cascade is for the cancer cells to invade surrounding 
tissue. An important involved program is epithelial-mesenchymal transition (EMT) 
83,84. In EMT, epithelial cancer cells use the mesenchymal properties to invade, resist 
apoptosis and spread to distant organs 84. The cells loose E-cadherin, a key cell-to-cell 
molecule, and upregulate N-cadherin, an adhesion molecule associated with cell 
migration during embryogenesis and inflammation 84,85. The reversed process is 
called mesenchymal-epithelial transition (MET) 86-88. This plasticity may result in the 
formation of new tumor colonies of cancer cells with a similar histopathology to the 
primary tumor cells that never went through EMT 52,89. Transforming growth factor β 
(TGF-β) signaling actives transcriptional factors, which induce gene expression 
patterns favoring EMT development 52,90. 
 
In RCC, Landolt et al found increased EMT score in ccRCC 90. The gene expression 
analysis related to EMT correlated to ccRCC patient survival in a public available 
dataset 90. These results show how EMT in ccRCC is linked to fibrosis and associated 
with reduced survival 90. 
 
 Sustaining proliferative signaling 
One of the most important features of cancer cells is the ability to sustain chronic 
proliferation 52. In the normal tissue, growth-promoting signals are controlled. In 
cancer cells, they find different ways to acquire the capability to sustain proliferative 
signaling 52. They can use autocrine proliferation, by producing growth factors 
themselves or send signals to normal tumor associated cells in the stroma to produce 
growth factors 52. They can also regulate the number of receptors on cell surface, to 
make cancer cells more responsive 52. And last, activation of downstream signaling 
pathways or change of negative-feedback mechanisms can make cancer cells 
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independent of exogenous growth factors 91. In RCC, the inactivation of VHL gene 
and upregulation of downstream HIF1α are examples of that. IL6 is important since it 
stimulates tumor cell proliferation and survival by activating pathways such as 
JAK/STAT, Ras/Raf/MEK/MAPK and PI3K/AKT pathway via gp130 tyrosine 
phosphorylation 75. In tumor cells, STAT-3 activation is mediated through autocrine 
production and paracrine secretion of IL6 from stroma and infiltrating inflammatory 
cells 75.  
 
 Evading growth suppressors 
Cancer cells can negatively regulate cell proliferation inhibitors 52. Tumor 
suppressors limit cell growth and proliferation 52. Two of the most important are the 
retinoblastoma associated (Rb) and tumor protein 53 (TP53) proteins 52. These two 
controls the decisions of cells to proliferate or activate senescence and apoptotic 
programs 52. RB is the gate-keeper in the cell-cycle from G1 to S. TP53 can halt the 
cell-cycle progression, dependent on intracellular conditions dependent on genome 
damage, levels of nucleotide pools, growth-promoting signals, glucose or 
oxygenation are suboptimal 52. If needed, TP53 can induce apoptosis 52. More than 
half of human tumors contain a mutation in the TP53 gene 92,93. A meta-analysis 
showed how positive TP53 expression was correlated with a poor prognosis and 
advanced clinicopathological features in patients with RCC 94. IL6 is involved in 
hyper methylation of tumor suppressor genes via CpG methylation of the promoter 
region of the TP53 gene 75. In multiple myeloma cells, IL6 facilitates the 
phosphorylation of Rb that promotes cell growth 75. 
 
 Enabling replicative immortality 
The telomeres protect the ends of chromosomes from fusion and DNA degradation 52. 
Telomeres are centrally involved in the capability for unlimited proliferation of 
cancer cells 52,95. Normal cells have a limited number of cell growth-and-division 
cycles. They are related to two barriers of proliferation: senescence, a typical 
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irreversible entrance into a non-proliferative state and crisis, which involves cell 
death 52. Telomerase is the unique DNA polymerase that extend telomeres and 
enables replicative immortality 52. Telomeres can also propagate proliferation of 
cancer cells and not only maintain telomere length 52. The human telomerase reverse 
transcriptase protein (hTERT) synthesis de novo telomere, and in a recent paper 
hTERT expression was significantly associated in ccRCC with an advanced stage, 
higher grade, presence of microvascular invasion, lymph node invasion, and 
metastasis 96.  
 
 Resisting cell death 
Apoptosis is a normal process important for normal embryogenesis and maintaining 
homeostasis 52. The programmed cell death by apoptosis represents a barrier for 
cancer development 52. It is initiated in response to different stimuli like DNA 
damage, deregulated growth signals and hypoxia 52. Apoptosis is controlled in two 
major ways. The extrinsic receiving and processing extracellular death-inducing 
signals, and the intrinsic, which is sensing and integrating a variety of signals of 
intracellular origin and more widely considered a barrier to cancer pathogenesis 52. In 
cancer, IL6 is shown to induce JAK/STAT3 and NF-kB signaling to translocate 
STAT3 and NF-kB in the nucleus 75. Activation of these signaling pathways results in 
the expression of anti-apoptotic genes (i.e. Bcl-2) 75. Proteins of the BCL-2 family 
regulate the pro and anti-apoptotic signals in cancer, loss of TP53 function can 
increase or downregulated these proteins 75. In RCC, TP53 may be a prognostic 
marker (see chapter 1.5.6). 
 
Another important cell-physiologic response is autophagy, which is a normal process 
increasing substantially because of cellular stress 52. Cells use the autophagy program 
cells to break down cellular organelles, like ribosomes and mitochondria, to be 
recycled and used for biosynthesis and energy metabolism 52. Elevated levels of 
autophagy can be induced by nutrient starvation, radiotherapy and certain cytotoxic 
drugs, paradoxically impairing and not activate the killing actions of these stress-
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inducing situations 52,97. Further, many stressed cancer cells have been shown to 
shrink via autophagy to a state of reversible dormancy, and may enable regrowth of 
cancer cells after anti-cancer treatment 52,97. 
 
 Reprogramming energy metabolism 
Otto Warburg found a feature of cancer cell energy metabolism, where cancer cells 
even in an aerobic state cancer cells can reprogram their glucose metabolism and the 
energy production to glycolysis 98,99. The cancer cells do this by upregulation of 
glucose transports, like GLUT1, which pump glucose into cells 52. This metabolic 
switch is a way for cancer cells to generate nucleosides and amino acids from 
glycolytic intermediates to be used in the biosynthesis of the macro molecules and 
organelles necessary for new cancer cells 52,100. HIF1α signaling regulates glucose 
metabolism in response to hypoxia and growth factors 101. In RCC, constitutive 
expression of HIF1α target genes contributes to aerobic glycolysis and IL-6 induces 
fatty acid oxidation in the mitochondria by activating the AMPK pathway 101.  
 
1.6  Prognostic and predictive markers 
The Biomarkers Definition Working Group uses a broad formulation;  
“a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” 102.  
 
 Biomarkers 
Biomarkers are used to guide treatment of cancer patients. Prognostic markers can 
divide the clinical outcome of different patient subgroups assuming the patients will 
receive either no treatment or a form of standard treatment such as surgery or 
radiation 103. An excellent prognostic factor may therefore identify patients that not 
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need standard treatment, even if it has activity 103. If further therapy is necessary, 
predictive markers, can help to identify patients who may have benefit of further 
treatment such as targeted therapies or immune checkpoint inhibitors 103. 
 
Predictive biomarkers identify patients who will most likely to benefit from treatment 
104,105. A predictive biomarker can also be a prognostic biomarker.  
 
Few biomarkers have advanced beyond the clinical validity phase, even many 
biomarkers have been reported 103. The phase of clinical validity show how a 
biomarker has a strong association with a clinical outcome of interest 103. According 
to Kern et al it is said that of all cancer biomarkers investigated only 1% get into 
clinical practice, and neglecting this difficulty is a general failure to validate 
clinically that a marker has utility 106. The power to change a clinical decision arises 
from the predictive marker’s value or strength to categorize among disease 
classifications 106. Simon et al proposed that a prospective-retrospective study must 
be confirmed by at least one additional prospective-retrospective study to establish 
clinical utility of a marker, compared to a prospective clinical trial that directly 
addresses clinical utility of the marker 103,107. The statistical power to evaluate a 
marker’s clinical utility within a trial can be difficult if the study originally was 
designed to answer a question of treatment efficacy 103. Patient populations or 
biomarker assays used in different studies will variate 103.  
 
In their paper, McShane and Hayes point on three types of reporting biases, that are 
major threats to determine the clinical utility of tumor marker 103. The first is the non-
publication bias, where researchers decide not to report negative studies 103. The 
second they call “within-publication selective reporting”, where researchers select 
only a subset of study outcomes 103. Authors then fail to provide a rationale for the 
selection of cut point 103. The third type of bias is the “incomplete study reporting”, 
where too few details are reported to reproduce properly 103. 
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In an effort to improve reporting of biomarker studies governments, journals and the 
research field have taken action. One method was to establish trial registries of 
prospective studies, like ClinicalTrials.gov in the United States, which gives an 
overview of unpublished studies 103.  
 
Another important step to improve reporting was the introduction of the CONSORT 
(Consolidated Standards of Reporting Trials) statement 108. The updated statement in 
2010 includes a flow diagram and checklist of items to report and to describe; the 
flow of patients through the study, primary and secondary end points, prespecified 
hypotheses, key aspects of the study design and methods, the prespecified statistical 
analysis plan, and results 103,108,109.  
 
Further, to have more rigorous and transparent criteria for publication of tumor-
biomarker studies, the Biospecimen Reporting for Improved Study Quality (BRISQ) 
and the Reporting Recommendations for Tumor Marker Prognostic Studies 
(REMARK) guidelines were developed 103,110-112. This kind of documentation should 
be an essential component for publication in high-impact journals of biomarker data 
that contribute to support clinical utility 109.  
 
Biomarker development failures have consequences in form of lost resources from 
funding, time and labor, waste of talent, and give bad credibility for the field 106. The 
volume of misleading publications may raise false hopes, ethical dilemmas, triggering 
the wrong policy changes or unnecessary political debates 106. To treat patients with 
drugs that may not have an effect are expensive. Biomarkers are important to find and 
use. Rini et al wrote: “The ideal biomarker would be simple, reflective of intended 
target inhibition, easy to measure, of low cost, and reliably present at the baseline or 
early after initiation of therapy” 113. And Hayes et al argues that “When patient 
management is dependent on the results of a biomarker test, that test becomes as 
critical for patient care as a therapeutic agent” 109.  
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 Prognostic markers in metastatic RCC 
Prognostic biomarkers give information about cancer outcome, regardless of therapy 
105. To improve prognostic information, targeted treatment uses prognostic models for 
clinical trial design, patient consulting and risk-assessment 114. 
  
In treatment of metastatic RCC, a widely used risk score model have been a modified 
version of the Memorial Sloan-Kettering Cancer Center (MSKCC) model, originally 
made for INFα and/or IL2 treatment of ccRCCs 114-117. To improve the model, 
adjusted to anti-VEGF treatment, the International Metastatic RCC Database 
Consortium (IMDC) found six independent prognostic markers (see Table 1) 118. 
Results of this work in the new model added elevated platelet count and excluded 
lactate dehydrogenase (LDH), because of lack of statistical significance in the 
multivariate analysis 118. The model includes Karnofsky performance status of less 
than 80%, less than 1 year from diagnosis to treatment, anemia (hemoglobin 
concentration < lower limit of normal), hypercalcemia (corrected calcium 
concentration > upper limit of normal), neutrophilia (neutrophil count > upper limit 
of normal), and thrombocytosis (platelet count > upper limit of normal) 114,118. The 
model has been externally validated 114,119. 
Table 1  
Parameter Score 
KPS < 80% 1 point 
Time < 1 year from diagnosis to treatment 1 point 
Hemoglobin < LLN 1 point 
Calcium > ULN 1 point 
Neutrophils > ULN 1 point 
Platelets > ULN 1 point 
  
IMDC score Total score 
Favorable 0 point 
Intermediate 1-2 points 
Poor 3-6 points 
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The TNM classification is an anatomical prognostic marker to give information about 
probability of survival 32,33. Tumor size, venous invasion, renal capsular invasion, 
adrenal involvement and lymph node and distant metastasis are included 32. 
 
The ISUP grading system has replaced the Fuhrman grading 44. The grading system 
estimates the prognosis of the patient’s disease burden. Tumor grade, subtype of 
RCC, sarcomatoid features, microvascular invasion, tumor necrosis and invasion of 
the collecting system are histological factors 44.  
 
CRP is an acute-phase protein increasing rapidly following IL6 secretion by 
macrophages and T cells following infection, inflammation and cancer 79. It is an 
established biomarker for systemic inflammation, available in most clinical datasets, 
and provides prognostic information in several cancers including RCC 120.  
 
NLR is also a marker of systemic inflammation in cancer patients and was found to 
add prognostic and predictive information in RCC in retrospective studies 81,82. 
Among patients with baseline NLR ≤ 3 median PFS was significantly better than 
patients with baseline NLR > 3 (median PFS, 14.7 months vs. 6.7 months, Log rank p 
= 0.05) 121.  
 
Baseline health related Quality of Life (HRQoL) questionnaire is a method where 
patients self-determine their own function, symptoms and global health 122,123. 
HRQoL evaluation of patient-reported baseline QoL symptoms can be a prognostic 
indicator of survival times in clinical trials and practice 123,124. Using the FACT-
Kidney Symptom Index-15 (FKSI-15) score, Cella et al found a higher score (fewer 
symptoms) at baseline to be linked with median PFS and OS in metastatic RCC 
patients 124. Using the EORTC QLQC30, another group found that “global QoL” was 
prognostic for PFS 125. 
 
IL6 and IL6Rα are negative prognostic markers of survival in both primary and 
metastatic RCC 71,126-128. IL6, is an immune system related cytokine, and has a role in 
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inflammation, infection responses, and the regulation of metabolic, regenerative, and 
neural processes 67,71,129,130. High levels of inflammation-associated cytokines are 
negative for the outcome of treatment 130. Elevated IL6 has been associated with poor 
survival in RCC and resistance to rTKI treatment 127,131-133. IL6 and IL6Rα co-
expression might be an independent early stage immunological prognostic factor for 
patients with organ-confined ccRCC 134. However, high serum IL6 was significantly 
associated with better PFS in patients treated with pazopanib vs. placebo 135.  
 
Dornbush et al found an association between high expression of VEGFR2 and good 
treatment response 136, and Terakawa et al also found high expression of VEGFR2 to 
be beneficial to sunitinib treatment 137.  
 
High expression of HIF2α and PDGFRβ in tumor tissue were associated with better 
response of sunitinib treatment 138. In another study, elevated level of perivascular 
PDGFRβ was found to be a marker of poor prognoses in RCC 139.  
 
 Predictive markers in metastatic RCC 
Predictive biomarkers identifies patients who will most likely respond to a 
therapeutic intervention 105. A controlled study is mandatory to introduce a predictive 
marker. The best way is to have a comparison of a treatment to a control in patients 
with and without the biomarker. The ongoing search for biomarkers to optimize 
VEGF inhibitor treatment in RCCs has so far been unsuccessful in finding predictive 
biomarkers useful in the clinic. Until recently there is no such biomarker validated for 
VEGF targeted therapy in metastatic RCC 140,141. It would be of great value to 
identify, with help of predictive markers, which patients are most likely to benefit 
from the treatment 104.  
 
The CheckMate 214 trial is probably the only validated study demonstrating IMDC 
as a predictive biomarker in first-line treatment of mRCC 142,143. In the trial, they 
demonstrated significantly higher OS and objective response rates with nivolumab 
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plus ipilimumab than with sunitinib among intermediate and poor-risk patients with 
previously untreated mRCC 142.  
 
A possible predictive marker is CRP shown in a phase two study where baseline CRP 
was significantly associated with objective response (Mann Whitney, p = 0.01) 121. 
Fujita et al. showed that normal level of baseline CRP was an independent predictive 
marker of response in multivariate analysis 144. 
 
In immune checkpoint inhibitor treatment, PD-L1 expression have not been 
conclusive to be a predictive marker, because of effect of treatment regardless of PD-
L1 tumor expression 142,145. 
 
 On treatment markers 
Prognostic factors are based on patient information at baseline derived from 
retrospective analyses of large cohorts of patients. They are dynamic and can change 
during treatment 114,146.  
 
Development of early hypertension at week 12 under sunitinib treatment was 
associated with an improved clinical outcome and patients with induced 
hypothyroidism had longer PFS 113,147,148 
 
Donskov et al have demonstrated how on-treatment neutropenia and hypertension 
were significantly associated with longer PFS and longer OS 149, and hand–foot 
syndrome with longer OS, independent of baseline prognostic factors, including the 
IMDC risk criteria 146. Adding the five-factor biomarker profile significantly 
improved prognostication in the IMDC intermediate (25.7 months vs. 12.0 months) 
and poor (12.8 months vs. 6.4 months) risk groups and a trend was seen in the IMDC 




Tumor stage and disease burden determine the treatment choice of RCC. Current 
European guidelines are used in treatment of patients with localized or metastatic 
RCC in Norway 37,38.  
 
 Treatment of localized and locally advanced RCC 
Surgery  
A in depth description of the surgical treatment of localized RCC is beyond the scope 
of this introduction. Thus, only a brief overview is presented. Open radical 
nephrectomy (RN) was for four decades the standard of surgical care for RCC 150. 
Partial nephrectomy (PN) is now standard for organ-confined tumors at the renal 
poles measuring <7 cm (T1 disease) 151. PN in any method is the treatment choice in 
patients with T1 tumors rather than minimal invasive RN 38. There is no survival 
benefit of removing lymph nodes without evidence of lymph node metastasis  38. 
There is clear evidence demonstrating that laparoscopic RN has lower morbidity than 
open surgery 38. Thus, it is now recommended for patients with T2 tumor and for T1 
not treatable by PN 38. Localized (T1 and T2) tumors can be cured by surgery alone 
38. The 5-year PFS for T1 and T2 disease is 95% and 74%, respectively 152. In patients 
with locally advanced (T3 and T4) there is no survival benefit to remove the adrenal 
or lymph nodes without evidence of adrenal or lymph node involvement 151,153. 
 
Surgery is indicated in patients with non-metastatic RCC and venous tumor thrombus 
38. In a large study published, a higher level of thrombus was not associated with 
increased tumor dissemination to lymph nodes, perinephric fat or distant metastasis 
38. As most methods have similar oncological outcome, the choice of methods for 
locally advanced tumors will depend on the skills and experience of the surgeon 38.  
 
Post-surgery the TNM score system, the Leibovich score system and AJCC staging 
give prognostic information 32,33,152,154, and can be used to stratify patients with regard 
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to prognosis. A risk stratified follow up regimen is recommended because of risk of 
relapse within the first five years after surgery 155. Also to be mentioned, a 
management option in elderly and/or comorbid patients with small renal masses not 
candidates for surgery may be active surveillance 38. This is done by using serial 
abdominal imaging of tumor 37. As the growth of small renal masses is slow in most 
cases, and progression to metastatic disease is rare 38,156, many patients can avoid 
surgical intervention. A renal biopsy is recommended before active surveillance. 
Other options of poor surgical candidates are radiofrequency ablation and 
cryoablation 38.  
 
Adjuvant therapy 
Despite high recurrence rates for patients with locally advanced (T3 and T4) disease, 
adjuvant therapy has not proven to be beneficial in randomized phase III trials 153.  
 
Several studies have failed to demonstrate significant improvement in OS using 
adjuvant treatment 38. These studies included use of immunotherapy (IFN-α, IL2, 
autologous tumor vaccines) and use of anti-angiogenic or targeted therapy (sunitinib, 
sorafenib, pazopanib, girentuximab) 37,157-160. Neither do adjuvant cytokines improve 
survival after nephrectomy 38.  
 
Ravaud found, in the S-TRAC study, that a sub group of patients with locoregional 
RCC at high risk for tumor recurrence after nephrectomy had a longer duration of 
disease-free survival (DFS) than those receiving placebo 160. The results showed a 
benefit of sunitinib over placebo for DFS (HR: 0.76; 95% CI: 0.59-0.98, p = 0.03) but 
data for OS remained immature 160. In a follow-up study, George et al found in the 
sunitinib group, a potential predictive marker where increased density of CD8+ cells 
was beneficial for DFS 161. The ASSURE study, was a large adjuvant study 
investigating sunitinib versus sorafenib versus placebo 162. The updated analysis in 
2018 did not show a significant difference in disease free survival 162. 
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The PROTECT study, was a study investigating pazopanib versus placebo 159. The 
study did not meet the primary end point of DFS in the intention to treat group 
receiving 600 mg, but in the group receiving full dose therapy (800 mg) there was an 
improvement in DFS (HR: 0.69; 95% CI: 0.51-0.94, nominal p = 0.02) 159.  
 
Based on the results European guidelines do not recommend sunitinib in the adjuvant 
treatment of high-risk RCC after nephrectomy 38.  
 
 Treatment of advanced/metastatic RCC 
Surgery 
Cytoreductive nephrectomy (CN) and metastasectomy are options in metastatic RCC 
38. Curative treatment is only possible if the removal of all tumor tissue is removed 37. 
In a minority of metastatic RCC, CN and metastasectomy are indicated as palliative 
treatment for pain relief or uncontrolled bleeding 151. CN with simultaneous resection 
of single metastasis or oligo metastases may improve survival and delay systemic 
therapy 38. 
 
Earlier, IFN-α and IL2 were the systemic treatment options and two randomized 
studies showed a survival benefit for CN plus IFN-α versus IFN-α alone 163,164. After 
the introduction of targeted therapy, TKI’s were used in similar fashion, and 
retrospective studies reported that patients with CN had better survival than those 
only treated with targeted therapy 165,166. In a meta-analysis, CN increased OS in 
patients with metastatic RCC that were treated with targeted therapy with CN versus 
those without CN 167. However, these retrospective studies were flawed by selection 
bias because of patients undergoing CN had significantly better performance score 
compared with the non-CN patients 38. 
 
To investigate this further, two prospective randomized clinical trials (SURTIME and 
CARMENA) were performed. In SURTIME, time of CN in relation to sunitinib 
treatment was investigated. OS was better in the group of deferred versus immediate 
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CN 168. In the CARMENA study, CN plus sunitinib versus sunitinib alone in patients 
with metastatic RCC at presentation did not find a difference in OS 169. Both studies 
were closed prematurely due to slow recruitment. Both studies have been criticized 
for statistical power issues and their general validity. However, based on these two 
studies recommendations have changed. Today CN is only recommended in highly 
selected patients that do not have poor IMDC risk score, small primaries, high 
metastatic volume and/or a sarcomatoid tumor component 166. 
 
There are no randomized studies on metastasectomy 38. Except for the brain and 
maybe bone metastases, there is generally a weak recommendation for 
metastasectomy 38. In 2014, a systematic review reported that patients with metastatic 
disease and favorable risk score could be offered a resection or ablation to achieve 
complete resection 38,170. Standard treatment is to continue regular radiological 
surveillance 38,153.  
 
Systemic therapy 
First line treatment 
Targeted therapy is the standard of care in systemic treatment of advanced disease. 
Until recently, anti-angiogenic treatment was the first line treatment for all risk 
groups 38. Sunitinib, a receptor tyrosine kinase inhibitor (rTKI), is currently the 
primary choice 116. Similar rTKIs are sorafenib, pazopanib and axitinib 171-173. Other 
important drugs are the mTOR inhibitors temsirolimus and everolimus 174,175. 
Sunitinib or pazopanib is first line treatment in the IMDC favorable risk group 
whereas ipilimumab/nivolumab combination immunotherapy is first line treatment 
option in the intermediate and poor risk group 176. Recently new studies showed 
improved benefit of immune checkpoint inhibitors, compared with rTKI, in first line 
treatment and will probably change future treatment regime 142,145,177-179.  
 
Sunitinib (SU11248) marketed, as Sutent by Pfizer, is an oral multi targeted tyrosine 
kinase inhibitor. It was FDA approved 2006 and introduced as the preferred anti-
angiogenesis therapy for metastatic ccRCC 27,116,180,181. Sunitinib was superior to IFN-
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α treatment (PFS, 11 months vs. 5 months, HR 0.42 (95% CI, 0.32 to 0.54; p < 0.001) 
116. It was developed as a drug targeting angiogenic receptors on endothelial cells 182-
184.  
 
Sunitinib inhibits several receptors like; VEGFR-1, -2 and -3, PDGFR α and β, 
fibroblast growth factor receptor 1, proto-oncogene cKIT, fms-related tyrosine kinase 
3 (FLT3), ret proto-oncogene, rearranged during transfection (RET) and colony 
stimulating factor 1 receptor. In experiments, it is also shown to downregulate 
myeloid-derived suppressor cells as part of the anti-tumor effect 184.  
 
Sunitinib reach maximum concentration 6-12 hours after administration. The drug is 
metabolized by cytochrome P450 3A4 (CYP3A4), which makes it important to avoid 
or adjust drugs or foods affecting CYP3A4. Elimination is through feces and urine. 
There is no need of adjustment because of renal dysfunction or mild hepatic 
malfunction.  
 
The rationale behind sunitinib in metastatic ccRCC treatment is the anti-angiogenic 
effect. The frequent inactivation of the VHL gene in ccRCC, leads to increased levels 
of HIF1α and VEGF 27.  
 
The most common adverse events are fatigue, diarrhea, stomatitis, hand-foot skin 
reaction and hypertension 121,185. The sunitinib dose or administration can be adjusted 
for a more tolerable adverse events profile 186,187.  
 
Pazopanib was approved after being shown to be superior to placebo (median PFS, 
9.2 months vs. 4.2 months; HR, 0.46; 95% CI, 0.34-0.62; p < 0.0001) 172 and was 
non-inferior to sunitinib in a first line setting 171. Sunitinib and pazopanib share 
similar adverse events and in one trial pazopanib was preferred over sunitinib by the 
patients 188.  
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Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is a 
downstream effector of the PI3K/AKT pathway 153. mTOR has been found to 
increase HIF at the translational level, therefore inhibition of mTOR can be useful in 
RCC 153,189. 
 
Intravenous temsirolimus is a competitive inhibitor of the mTOR complex 1. It can be 
used as first-line treatment in poor-risk ccRCC patients and was shown prolonged 
survival over IFN-α among poor-risk patients 174. Sunitinib and pazopanib have also 
shown effect in the poor-risk patient group and may be preferable due to an oral route 
of administration 49.  
 
The monoclonal anti-VEGF treatment bevacizumab with IFN-α can be used in first-
line treatment. It was approved in the first line in metastatic RCC based on two phase 
three trials, showing the addition of bevacizumab to IFN-α extended PFS to eight to 
10 months versus five months 190,191. The combination is less used, because of oral 
TKIs, like sunitinib and pazopanib in first-line treatment 153.  
 
Second line treatment 
After progress on first-line rTKI patients can have second-line rTKI or mTOR 
inhibitors as temsirolimus or everolimus 153,175,192. Everolimus was approved on the 
basis of the phase 3 randomized trial (RECORD-1), which compared everolimus with 
placebo, in patients who had progress on sunitinib or sorafenib 175. Axitinib was 
associated with a longer PFS than sorafenib among patients treated with one previous 
line of therapy (predominantly sunitinib or cytokines) 49,173. 
 
Despite an improved outcome nearly all patients develop resistance to anti-VEGF or 
mTOR treatment 49. Combination therapy to overcome resistance has been tested 
without better effect in three studies 193-195. In a phase 2 study, everolimus plus 
lenvatinib versus everolimus showed increased PFS and OS 49,196,197. Lenvatinib is a 
dual VEGF-fibroblast growth factor inhibitor and start doses were reduced to avoid 
high level of toxicity 49,196.  
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The mechanism of acquired resistance to rTKI treatment stay largely unknown, but 
non-VEGF pathways involved in angiogenesis, invasion and proliferation may be of 
importance 49. Pathways of tyrosine kinases FGFR, MET and AXL are examples of 
targets involved in resistance to anti-VEGF therapy 49. Cabozantinib is a TKI, 
approved for metastatic medullary thyroid cancer that inhibits VEGF, MET and AXL 
implicated in the pathogenesis of RCC or the development of resistance 153. In a 
phase 3 study (METEOR), cabozantinib showed a significant PFS advantage versus 
everolimus, with median PFS 7.4 months in the cabozantinib group versus 3.8 
months in the everolimus group (HR for progression or death, 0.58; 95% CI, 0.45 to 
0.75; P<0.001) 198.  
 
Immunotherapy 
Immune checkpoint inhibitor 
In modern immunotherapy, immune checkpoint inhibitors have shown promising 
results. Immune checkpoint inhibitors with monoclonal antibodies targets and blocks 
the inhibitory T-cell receptor PD-1, the ligand (PD-L1) or cytotoxic T-lymphocyte 
associated antigen 4 (CTLA-4)-signaling to restore tumor-specific T-cell immunity 
38,199. Ipilimumab is an inhibitor of antigen four receptor (CTLA-4) expressed on 
cytotoxic T-cell. Nivolumab and pembrolizumab inhibit the programmed death 1 
(PD-1) receptor expressed on macrophages, T- and B-cells and atezolizumab (PD-L1) 
inhibits the ligand 142,145,177-179.  
 
Nivolumab was shown to have better OS, better QoL and less grade 3 and 4 adverse 
events compared with everolimus, in metastatic ccRCC after one or two lines of 
targeted treatment 177. The Checkmate 214 study (NCT 02231749) investigated the 
combination of nivolumab plus ipilimumab versus sunitinib study in treatment naïve 
advanced or metastatic ccRCC 142. At a median follow-up of 25.2 months in 
intermediate and poor-risk patients, the 18-month overall survival rate was 75% (95% 
CI, 70-78) with nivolumab plus ipilimumab and 60% (95% CI, 55-65) with sunitinib; 
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the median OS was not reached with nivolumab plus ipilimumab versus 26.0 months 
with sunitinib (HR for death, 0.63; p < 0.001) 142. Based on these results the 
guidelines recommend to use ipilimumab plus nivolumab in treatment-naïve patients 
with clear-cell metastatic RCC of the IMDC intermediate and poor risk score 38.  
 
The latest immune checkpoint inhibitor trials show a response benefit in first-line 
treatment, in treatment naïve patients 179. The Keynote 426 study, an open label phase 
3 trial, found significantly increased median PFS among patients treated with 
pembrolizumab plus axitinib versus sunitinib (PFS, 15.1 months vs. 11.1 months; HR 
for progression or death, 0.69; 95% CI, 0.57-0.84; p < 0.001) 179. The objective 
response rate was 59.3% (95% CI, 54.5-63.9) in the pembrolizumab plus axitinib 
group and 35.7% (95% CI, 31.1-40.4) in the sunitinib group (p < 0.001). The benefit 
was across all IMDC risk scores and regardless of PD-L1 expression 179.  
 
The PD-L1 inhibitor avelumab was tested with axitinib versus sunitinib in another 
phase 3 study in treatment naïve patients with advanced RCC 178. The study reported 
the results dividing PD-L1 positive tumors versus PD-L1 negative tumors 178. In PD-
L1 positive tumors, median PFS was 13.8 months with avelumab plus axitinib versus 
7.2 months with sunitinib (HR for progression or death, 0.61; 95% CI, 0.56-0.84; p < 
0.001) 178. The objective response rate was 55.2% versus 25.5%, in the two groups 
respectively. The PD-L1 negative tumors were not reported as a subpopulation in the 
study, but only as part of overall population 178. PFS in the overall population was 
13.8 months with avelumab plus axitinib versus 8.4 months with sunitinib (HR for 
progression or death 0.69; 95% CI, 0.56-0.84; p < 0.001) 178.  
 
In the IMmotion 151, a phase 2 trial, the results showed improved PFS for 
atezolizumab plus bevacizumab versus sunitinib in both PD-L1 positive patients and 
showed a favorable adverse event profile 145. Median PFS was 11.2 months with 
atezolizumab plus bevacizumab versus 7.7 months with sunitinib (HR 0.74; 95% CI, 
0.57–0.96; p = 0.0217) 145. The study needs longer observation time to establish 
possible survival benefit 145.  
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Interferon-α monotherapy and combined with bevacizumab 
Targeted therapy has taken over for interferon-α (IFN-α) in metastatic ccRCC 116. A 
Cochrane meta-analysis confirmed that IFN-α may still be effective in some patients 
groups 38,200. IFN-α had low response rate (< 15%) 115. The best benefit seems to be 
for patients in the favorable-risk group according to MSKCC risk score, where the 
median survival time was separated by 6 months or more in between the three risk 
groups 117.  
 
Along with the sunitinib versus IFN-α results 116, Escudier et.al. found better efficacy 
in patients treated with bevacizumab plus IFN-α versus IFN-α monotherapy 190.  
 
Interleukin-2 
Interleukin-2 (IL2) affects tumor growth by activating lymphoid cells in vivo without 
affecting tumor proliferation directly 201. Treatment response rate is from 7% to 27%. 
High dose of IL2 have increased toxicity and often observation and treatment in 
intensive care unit is needed 201. In one study there was 4% treatment related deaths 
202. 
 
Vaccines and targeted immunotherapy 
Cancer vaccines can enhance anti-tumor immunity, by presenting tumor antigens to 
T-cells 153. Examples of vaccines can be autologous tumor cells, peptide-based 
vaccines and dendritic cell-based vaccines. There are experimental studies ongoing. 
One study with a tumor antigen 5T4 plus a first-line standard treatment did not show 
survival benefit compared to placebo or first-line standard therapy 203. In IMPRINT, a 
phase 3 study, IMA901 a peptide-based cancer vaccine, aiming to increase the 
number of tumor-specific T cells did not find a survival benefit. They tested IMA901 
plus sunitinib versus sunitinib 204.  
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Dendritic cells can migrate in response to inflammatory signals to the lymph nodes 
and present T cells to stimulate an anti-tumor immune response 153. To make an anti-
cancer vaccine it is necessary to collect patient’s dendritic cells and culture them in 
vitro, prime them with antigens and then re-infuse into the patient 153. There was a 
phase 3 study (Clinicaltrials.gov, NCT01582672), investigating AGS-003, an 
autologous dendritic cell-based vaccine plus sunitinib versus sunitinib, but it was 
stopped because of lack of efficacy 205.  
 
Chemotherapy 
Chemotherapy is not recommended in modern treatment of metastatic RCC. In one 
study, there was small effect with 5-fluorouracil combined with immunotherapeutic 
agent 206 and one study showed similar OS between IFN-α versus a combination 
therapy of IFN-α, IL-2 and 5-fluorouracil 207. For patients with a poor prognosis, 
either with sarcomatoid histology or rapidly progressive RCC, gemcitabine and 
doxorubicin in combination could be used 208,209.  
 
Radiotherapy 
Traditionally, RCC is regarded a relatively radioresistant disease and the use of 
radiotherapy has been considered without effect in curative therapy of RCC. There is 
some evidence that use of palliative radiotherapy to bone or brain metastases can 
induce significant relief from local symptoms 38. 
 
1.8 Health-related Quality of Life 
Historical development 
Aristoteles (384-322 BC) thought that the role of the health-care system was to 
improve patient’s quality of life 210. WHO defines quality of life as: “Individuals’ 
perceptions of their position in life in the context of the culture and value systems in 
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which they live, and in relation to their goals, expectations, standards, and concerns” 
211,212.  
 
In modern medicine, the Karnofsky Performance Scale (KPS), was one of the first 
assessments of QoL in the early 1940s 213. KPS is part of the MSKCC risk score and 
the IMDC prognostic risk scores 117,118.  
 
Morton published a list of important subjects to be included in the QoL questionnaire 
214. Today the QoL questionnaire is called health-related QoL (HRQoL), which refers 
to the aspects of QOL related to a health or medical setting 215,216.  
 
HRQoL in RCC patients 
In RCC, reports of QoL have been related to surgical procedures 217-219.  
 
Considering the health of patients undergoing nephrectomy for localized tumor, 
Ames investigated the psychological needs using another questionnaire (The 
Functional Assessment of Cancer Treatment – General (FACT-G) 220,221.  
 
The EORTC have not developed or validated a disease-specific HRQoL 
questionnaire in RCC patients 122. In 2006 a symptom index where developed and 
validated (the Functional Assessment of Cancer Therapy (FACT) – Kidney Symptom 
Index (FSI). It is made of thirty-four symptoms related to the disease 124. In research 
projects in our hospital, the HRQoL questionnaire has been used in RCC and head 
and neck cancer 222-226. 
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2. Aims of the thesis 
2.1 General hypotheses 
Hypothesis: Patients with metastatic or inoperable kidney cancer with positive 
biomarkers of VEGF driven angiogenesis and VEGF associated immune suppression 
will have improved clinical benefit from treatment with an anti-VEGF-receptor 
kinase inhibitor. 
2.2 General aim 
Primary goal: To identify predictive markers of response in first line treatment with 
sunitinib against kidney cancer.  
Secondary goal: To estimate response, time to progression, survival and amount of 
patients with stable disease on treatment. 
2.3 Specific aims 
 Paper I 
To report the clinical data from hospital records including hospital blood samples, 
side effects and quality of life data. To evaluate the response rates from sunitinib 
treatment with use of the radiologic examinations.  
 Paper II 
To investigate potential predictive markers of response by immunohistochemistry in 
respect to angiogenic and immunogenic responses. To investigate these candidate 
markers in relation to clinicopathological data of paper 1.  
 Paper III 
To investigate potential predictive value of immune related biomarkers in serum and 
plasma of sunitinib response.  
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3. Material and methods 
3.1 Study design 
This PhD-project was based on a clinical phase II trial model conducted at the 
Oncology Department at Haukeland University Hospital in Bergen, Norway. The 
study was an open labelled, single arm, single institution clinical trial where patients 
with metastatic ccRCC in progression were treated with sunitinib monotherapy until 
disease progression, significant toxicity or consent withdrawal. Sunitinib was 
administered 50 mg/day on schedule 4 weeks on/two weeks off. Clinical evaluation 
was done every 6th week, and computer tomography (CT) was performed every 12th 
week for response evaluation. Biopsies and blood samples for research purposes were 
taken before the first treatment. Blood samples for research purposes were taken 
every 12th week. Data were collected from the hospital records and included 
demographics, treatment modifications, adverse events, radiologic response data and 
survival. Data cut-off date was July 31 2015.  
3.2 Ethics 
The study followed the ethical principles of the Declaration of Helsinki and the 
International Conference on Harmonization of Good Clinical Practice. The protocol 
was approved by the Regional Ethics Committee (REC number 080/07 and REC 
number 78/05)) and the Norwegian Medicines Agency. REC number 080/07 is the 
sunitinib study. REC number 78/05 is the kidney cancer biobank study. All 
participating patients provided signed informed consent before enrolment.  
3.3 Patient cohort and inclusion criteria’s 
Between October 2007 and October 2014, a regional cohort of 77 patients with 
mRCC was screened for inclusion at Haukeland University Hospital, Bergen, 
Norway. Forty-six patients were enrolled after signing the informed consent sheet. 
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Inclusion criteria included previously untreated metastatic or non-resectable ccRCC, 
WHO performance state 0-2, no known brain metastases, evaluable tumor lesions 




Metastatic or unresectable primary tumor of clear cell renal cell carcinoma 
WHO performance status 0-2 
Non-earlier cytokine treatment or other cancer treatment 
Radiation therapy against symptom given metastasis was possible, but not against lesion 
that we would like to evaluate response 
Non symptom given brain metastasis, but radiation treated brain metastasis where 
corticosteroids is stopped is allowed 
> 12 months since coronar bypass operation 
> 18 years 
Not pregnant or breast feeding 
Clinically or radiographic measurable disease according to the RECIST 
> 21 days since major surgery or damage 
> 2 days since biopsy, FNAC or central venous catheter 
No ongoing grade 3 bleeding 
None of the following the last 12 months: 
 -Myocardial infarction 
 -Serious unstable angina pectoris 
 -Symptomatic heart failure (not including EF < 50% or > 20% reduction of EF  
 compared to beginning of treatment) 
 -Stroke including TIA 
 -Pulmonary embolism 
No other active malignant disease or not been treated for other cancers the last five years 
Uncontrolled hypertension 
Uncontrolled arrhythmia, especially prolonged QT-interval and bradycardias 
Laboratory values of: 
 -Granulocytes > 1,5 x 10^9/L 
 -Platelets > 100 x 10^9/L 
 -Bilirubin and < 1,5x upper normal limit 
 -ASAT < 2,5x upper normal limit 
 -ALAT < 2,5x upper normal limit 
No other compliance that could make the patient unsuitable to be included in a research 
protocol 
Written consent from every patient 
Abbreviations: WHO: World Health Organization, RECIST: Response Evaluation Criteria in Solid 
Tumors, FNAC: Fine-Needle Aspiration Cytology, EF: Ejection Fraction, TIA: Transient Ischemic Attack, 
ASAT: aspartate aminotransferase, ALAT: alanine aminotransferase. 
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3.4 Response assessments 
 RECIST v1.1 
Response evaluation criteria in solid tumors (RECIST) v.1.0 was introduced in 2000 
and updated to v.1.1 in 2009 227. We used RECIST v.1.1 228. The major difference 
between version 1.0 and 1.1 is a maximum of five lesions to follow in v.1.1 versus 
maximum of 10 lesions to follow in v.1.0. If the patient has more than five lesions, 
the physician must choose five lesions that are possible to follow up over time. In 
both versions, non-target lesions were to be measured in case of progression. MP did 
the response evaluations, with advices from OS. 
 
Almost all patients did their computer tomography (CT) analyses at the department of 
radiology at Haukeland University hospital. A few patients (< 5) did their control CTs 
at their local radiology department because of the long travel distance. These CT 
scans were re-examined at Haukeland University hospital. CT contrast was used in all 
patients except in a few examinations due to development of renal failure.  
 
 Endpoints 
The primary endpoint was objective response (OR) defined as complete response 
(CR) or partial response (PR) according to RECIST v.1.1, as well as clinical benefit 
(CB) defined as CR + PR and including stable disease (SD) for more than 6 months 
228. Disease stabilization is considered beneficial to patients experiencing progression 
at the time of inclusion and CB is frequently included as an additional statistical 
endpoint in trials investigating antiangiogenic drugs in which therapeutic activity and 
clinical benefit are present, even in the absence of radiological tumor shrinkage 229. 
Importantly, all patients were in clinical and/or radiological progression at the time of 
inclusion. OR and CB were calculated based on investigator assessment. Response 
evaluation by CT-scan or MRI was performed every 12 weeks. In the final response 
evaluation, only CT-scans were used. Patients with clinically evident disease 
progression or death because of metastatic RCC before first radiological progression 
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were recorded as progressive disease (PD). Best overall response (BOR), recorded as 
change in size of target lesion, was unavailable in these patients. PFS was defined as 
the time from treatment initiation until disease progression according to RECIST 
v.1.1. OS was defined as the time from enrolment until death of any cause.  
 
Response status and endpoints at data cut-off date July 31 2015, were used in paper 
I, II and III. 
3.5 Toxicity 
Adverse events were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse events, version 3.0 (CTCAE v.3.0) 230, and were 
recorded at each 6-week cycle based on clinical evaluation, physical examination and 
outpatient ward blood tests.  
 
Patients that stopped treatment because of toxicity before first tumor response 
evaluation at week 12 were not included in the analyses of response rates or PFS, but 
were included in the analyses of OS. The complete list of adverse events is listed in 
the supplemental of paper I.  
3.6 Sampling of tissue and blood samples 
The biopsy material was prepared at the Department of Pathology, Haukeland 
University Hospital. Two formal-fixed paraffin embedded (FFPE) blocks were 
collected from external hospitals and one block was missing. Paraffin-embedded 
tissue was available in 45/46 (97.8%) patients in total. The most recent biopsy, from 
the metastatic lesion (n = 29) or from the non-resectable primary tumor, performed 
closest to the date of clinical trial inclusion (n = 12), was selected for further analysis 
if several lesions were available. In addition, protein expression of the candidate 
markers was analyzed in primary tumors alone (n = 41). All results in paper II 
referred to the most recent biopsy unless otherwise specified. All metastases and 
primary ccRCCs were reclassified by a RCC pathologist (LB) using the ISUP grading 
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system. Biopsies were investigated and scored on the hematoxylin and eosin slides to 
find the best FFPE tissue block to use in immunohistochemistry 
 
Full blood samples were collected at baseline before starting sunitinib and after every 
second cycle of treatment during the study time. After centrifugation, Na-heparin 
plasma samples were stored frozen at minus 80°Celsius. For ELISA we used the 
heparin plasma sample tubes, which were de-frozen in room temperature, shaken and 
then centrifuged for different amount of fibrin precipitation.  
 
In paper I, the regular hospital blood samples were used for baseline investigations. 
CRP was collected in 45/46 patients and the missing patient sample was one of the 
responders.  
 
The excellent staff in the research group did the work of biopsy preparation and blood 
sample collection.  
3.7 Clinicopathological variables 
The following variables were recorded: age, sex, WHO performance status, sites of 
metastases, number of disease sites, hypertension before treatment, IMDC risk score, 
time from initial diagnose, prior removal of primary tumor, adverse events, tumor 
size according to RECIST criteria, Quality of Life before and under treatment and all 
findings according to inclusion criteria.  
 
The TNM system used in the clinic during inclusion of patients in this study, was the 
6th 231 and 7th edition 232. In this work, all patients were stage four because of active 
metastatic disease at time of inclusion. 
3.8 Immunohistochemistry 
We used tissue sections of 4-5 µm from FFPE blocks from biopsies and resections of 
primary and metastatic RCC. Slides were deparaffined in Xylene and rehydrated 
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followed by antigen retrieval in a microwave oven. Endogenous peroxidase and 
alkaline phosphatase were blocked before incubation with the primary antibody 
followed by incubation with appropriate visualization kit. For negative controls, 
primary antibodies were omitted or specific blocking peptides were used for Heat 
shock protein 27 (HSP27) and VEGF-A. Tissues from different cancer types were 
used as positive controls. For JAG1, endothelial cells were used as positive internal 
control. Slides were stained with primary antibodies of IL6Rα, IL6, JAG1, VEGF-A, 




















































































































































1 JAG1: Secondary antibody: Rabbit anti-goat (6164-01). 
2 HSP27: Extra protein block: Dako X0909 and Secondary antibody: Rabbit anti-goat (6164-01). 
More details provided in supplementary table 1 in paper II 233    
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3.9 Evaluation of staining results 
Evaluation of staining results was performed by a semi-quantitative method. All 
sections were screened at x40 and x100 magnifications to map areas of cancer tissue 
and normal tissue. Further, with high power magnification (x200 or x400), staining 
intensity and the proportion of positive tumor cells were recorded implementing a 
semi-quantitative grading. Staining intensity was defined as absent (0), weak (1), 
moderate (2) or strong (3). The proportion was rated as “no positive tumor cells” (0), 
“less than 10% positive tumor cells” (1), “10–50% positive tumor cells” (2) or “more 
than 50% positive tumor cells” (3). The staining index (SI) is the product of intensity 
and area (range 0–9) 234,235. SI was used to quantify cytoplasmic staining of the 
antibodies. Cases were categorized into groups (absent/low vs. median/high protein 
expression) based on the SI distribution for each biomarker under investigation. 
Because of difference in distribution, there were different cut-points in the groups. 
The cut-points were set to: IL6Rα low (SI = 1-3) vs. median/high (SI = 4-9); IL6 
absent/low (SI = 0-2) vs. median/high (SI = 3-9); JAG1 absent/low (SI = 0-2) vs. 
median/high (SI = 3-9); VEGF-A low (SI = 1-3) vs. median/high (SI = 4-9); 
VEGFR2 absent/low (SI = 0-2) vs. median/high (SI = 3-9); PDGFRβ absent/low (SI 
= 0-1 vs. median/high (SI = 2-9); HSP27 low (SI = 1-3) vs. median/high (SI = 4-9). 
In addition, protein expression in tumor associated endothelial cells was graded based 
on staining intensity (0-3) for VEGFR2 and PDGFRβ. The IHC protein expression 
was evaluated and discussed by two observers (MP, OS) blinded with temporary 
number tags for response data.  
 
3.10 Analysis of blood samples 
 Enzyme linked immunosorbent assay (ELISA) 
MP found different manufactures of antibodies tested in human blood samples in 
patients with RCC. Of them, the ELISA kits were selected based on the experience of 
GHN. GHN carried out the experiments to increase the quality of the work and 
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because of shortness of time. MP observed the method. The antibodies used were 
human IL6 (P05231), human IL6Rα (BMS214) and human IL6ST (EHIL6ST). 
Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA provided all three. For IL6 
we used a ready-to-use self-coating system kit (Invitrogen) and an ELISA 96-well 
flat-bottom plate (Nune MaxiSorp flat-bottom, Invitrogen (catalog number 44-2404)). 
For IL6Rα we used a ready-to-use sandwich ELISA 96 micro well plate coated kit 
with human IL6Rα (Invitrogen). For IL6ST we used a ready-to-use self-coating 
system kit (Invitrogen). Phosphate buffered saline (PBS); containing 0.05% (v/v) 
Tween 20 (PBS-T) (Prod.nr. 822184, Merck, USA) was used as washing buffer. All 
other buffers used were from the respective ELISA kit. The staining process was 
performed according to the manufactures manual and was analyzed at 450 nm with a 
microplate reader (Molecular Devices Emax).  
 
 Evaluation of ELISA results 
We evaluated the ELISA results according to the manufactures manual. SoftMax Pro 
was used to evaluate the ELISA data and then transferred to SPSS for statistical 
analysis. We categorized the baseline ELISA variables (pIL6, pIL6Rα, pIL6ST), into 
low (below median) versus high (above median). The change in pIL6, pIL6Rα and 
pIL6ST concentration between baseline and week 12 were divided into three 
categories (decrease, stable, increase). We tested the decrease group versus the stable 
and increase groups. The variables referred in the paper III are baseline values if not 
otherwise specified.  
 
3.11 Health related Quality of life 
 The general HRQoL questionnaire EORTC QLQ C-30 
HRQoL was assessed by a validated Norwegian version of the questionnaire of the 
European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 
v.3.0) at baseline and every 12 weeks during treatment. The QLQ-C30 contains a 
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global health/QoL scale, five functional scales (physical, role, cognitive, emotional, 
and social), three symptom scales (fatigue, pain, and nausea/vomiting) and six single 
items (dyspnea, insomnia, anorexia, constipation, diarrhea, and financial difficulties). 
The answers were selected according to a 4-point Likert format, with the exception of 
questions about general health and quality of life, given according to a 7-point Likert 
format. Scores were calculated as described in the EORTC QLQ-C30 Scoring manual 
(3rd edition) 236. The C30 functional scales and the global scale were transformed so 
that 100% indicates best function and 0% least function of the individual QoL index, 
whereas the C30 symptom scales were transformed so 0% indicates the least and 
100% the most symptoms. We compared the upper quartile with the lower three 
quartiles for the symptom sum score and the lower quartile with the upper three 
quartiles for the functional sum score and global health/QoL score 121. 
3.12 Statistics 
Sample size calculations (alpha 0.05/power 80%) indicated 20 patients per group 
based on candidate marker expression were needed to detect a difference between 
10% and 50% of patients having a response to treatment with sunitinib. The Mann-
Whitney U test was used to compare the distribution of continuous variables between 
two groups like responders and non-responders. Comparisons between categorical 
variables were performed by using the Fisher’s exact test and Pearson chi-square. 
Spearman’s rank correlation coefficient was used to test correlations between 
variables of interest. Logistic regression analysis was used to test the relative 
importance of predictive factors for sunitinib response. Cronbach’s α was used to 
estimate the reliability of the global health score and the functional/symptomatic 
scores made up of more than one question. Kaplan-Meier estimates were applied for 
time-to-event endpoints like PFS and OS, and log rank-test was applied for testing of 
differences between groups. All p-values are two-sided. The significance level was 
0.05 for all tests. Statistical investigation was performed using IBM SPSS Statistics 
version 22 (paper I) and version 24 because of program update (paper II and III) 
(SPSS Inc., Chicago, IL, USA).  
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4. Summary of the results 
4.1 Paper I 
Seventy-seven patients were screened and 46 patients enrolled. The median age was 
63.1 (range 41.1-84.0). We observed 1 complete response (CR), 7 partial responses 
(PR) and 18 patients had stable disease (SD) ≥ 6 months. Twelve patients showed 
progressive disease (PD), of which 10 were confirmed by radiology and two were 
confirmed by clinical progress before week 12. Eight patients discontinued treatment 
before week 12 and were recorded as non-evaluable for response rates and PFS. Of 
these, six were due to toxicity without evidence of disease progression, one patient 
because of appendicitis and one protocol violation. Of interest, seven of these eight 
patients were females.  
 
Median PFS was 9.1 months (range 0.5-57.3 months) and median OS was 15.4 
months (range 1.8-83.9 months).  
 
The key finding was a significant association between normal CRP (≤ 10 mg/L) at 
baseline and OR (CR+PR) (Fisher’s exact test, p = 0.01). 7/17 (41%) of patients with 
normal CRP had an objective response to sunitinib, compared with 1/20 (5%) patients 
with elevated CRP had an objective response. Median CRP at baseline was 17.0 
mg/L (range 0-235 mg/L). Seventeen of 37 patients evaluated for overall response 
had normal CRP. Logistic regression analysis was used to test the relative importance 
of the candidate predictive factors for sunitinib response (eHTN, IMDC risk score, 
baseline NLR, baseline CRP, baseline EORTC QoL symptom scale). Only baseline 
CRP was an independent predictive variable of response, with an odds ratio of 14.3 (p 
= 0.02) of not having an objective response if CRP was above normal (10 mg/L). 
 
Baseline NLR was not significantly associated with OR or CB.  
 
 57 
Treatment induced early hypertension (eHTN), defined as SBP ≥ 140 or DBP ≥ 90 
mm Hg at week 6, was not significantly associated with OR or CB. In our population, 
the baseline blood pressure was slightly higher when compared with the clinical trial 
population studied 113, and 52% of our patients were hypertensive at baseline. Still, 
the number of patients recorded as having sunitinib induced eHTN after cycle 1 and 
2, using the same criteria, was nearly the same (~80%). eHTN at week 12 was 
associated with improved survival, but this is most likely because of the fact that the 
responders in the study stayed on treatment long enough to develop hypertension. 
Even if pharmacodynamically interesting, as eHTN occurs after sunitinib initiation it 
is not going to be an applicable predictive marker in the clinic.  
 
IMDC risk score was not significantly associated with OR or CB. 
 
The most frequent severe adverse events (grade 3+4) were hypertension (19.6%), 
fatigue (15.2%), low serum platelets (15.2%), hand-foot skin reaction (10.9%) and 
diarrhea (10.9%). We observed one grade 5 adverse event, death because of 
appendicitis, probably unrelated to sunitinib treatment. Only for “Fatigue”, there was 
a statistically significant increase in the score during treatment compared with the 
baseline value (Wilcoxon ranked signed test, p = 0.04) for the health related quality 
of life (HRQoL) questionnaires at baseline. A Symptom score in lower 3 quartiles 
was significantly associated to improved CB (Fisher’s exact test, p = 0.02). 
Investigating symptom sum scores indicated the upper quartile had significantly 
worse OS (median 12.7 months vs. 25.2 months, Log-rank p = 0.01) and PFS 
(median 2.9 months vs. 14.7 months, Log-rank p = < 0.01). No such difference could 
be demonstrated for global health/QoL status or functional sum score. 
4.2 Paper II 
In paper II, we investigated the potential predictive value of angiogenic, 
inflammatory and immunogenic factors in tissue samples for response to sunitinib 
treatment. We used immunohistochemistry to investigate tissue expression of IL6Rα, 
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IL6, JAG1, VEGF-A, VEGFR2, PDGFRβ and HSP27. Low expression of IL6Rα was 
significantly associated with OR (Fisher’s Exact test, p = 0.03). Sixty-six percent of 
the patients with response data available showed median/high expression of IL6Rα in 
tumor cells, and only 10% of these patients responded to treatment with sunitinib, 
whereas 46% of patients with low expression responded. Absent/low expression of 
IL6 was significantly associated with improved PFS (median PFS, 17.0 months vs. 
8.7 months, Log rank, p = 0.04).  
4.3 Paper III 
The purpose of paper III was to test if the inflammatory factors IL6 and IL6Rα in 
plasma could predict treatment response to sunitinib therapy. We assessed single 
ELISA assays. Plasma concentration of IL6 was significantly associated with CB 
(Fisher’s exact test, p < 0.01). Similarly, the continuous value of IL6 was 
significantly associated with CB (Mann-Whitney U-test, p < 0.01). Low IL6 was 
significantly associated with improved PFS (median PFS, 14.7 months vs. 5.3 
months, Log rank, p = 0.04). IL6Rα was not significantly associated with OR or CB. 
The High change in IL6 was significantly associated with decrease of IL6Rα 
(Pearson chi-square, p = 0.05). Low change in IL6Rα was significantly associated 
with OR (Fisher’s exact test, p = 0.01) and not CB. Decrease of IL6Rα was 
significant associated with OR (Pearson chi-square, p < 0.01) and not CB.  
 
We also investigated the association to markers of interest in paper I and II. Low 
pIL6Rα at baseline was significantly associated with under median of age (Pearson 
chi-square, p = 0.04) and hypertension at baseline (Pearson chi-square, p = 0.02). 
pIL6Rα was not significantly associated with CRP and tumor tissue expression of 
IL6Rα or IL6. 
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5. Discussion 
5.1 Discussion of materials and methods 
 Patients, study design and samples 
The study was a single arm, single institution clinical phase II trial to investigate 
potential predictive biomarkers of sunitinib treatment in patients with metastatic 
ccRCC. Seventy-seven patients were screened and 46 enrolled. The numbers of 
screening failures were because of other histology than ccRCC or lack of biopsy from 
primary tumor or metastases. Still, there were enough patients enrolled for statistical 
power, to find possible biomarkers of interest. The inclusion time ranged from 2007 
to 2015, in part because of the 42.8% screening failure. A great advantage of this 
study is the availability of tumor tissue, blood samples, clinical data, quality of life 
data and follow-up data.  
 
In paper I, the main objective was to identify and evaluate the predictive value of 
candidate markers readily available in a standard clinical setting, in metastatic ccRCC 
patients treated with sunitinib. Candidate markers included early hypertension 
(eHTN), IMDC risk groups, baseline NLR, baseline CRP and baseline EORTC QoL 
symptom scale. Response rates according to RECIST 1.1 were used as primary 
endpoint. Secondary objectives were to evaluate prognostic value of the candidate 
markers with regard to PFS and OS. In addition, toxicity rates and HRQoL were 
recorded. 
 
Because of ethical reasons, the study only had a single arm, since there was no 
acceptable control treatment available and placebo was impossible. All patients were 




All antibodies were first tested on sections of tissue microarrays containing cores of 
different tumor tissues including ccRCC.  
 
We used protocols from the immunohistochemistry research laboratory with 
adjustments to optimize the procedures. The time of tissue fixation in formalin is an 
unknown variable when working with archival FFPE blocks. Different fixation times 
can result in inhomogeneous immunohistochemical staining. To optimize demasking 
of the epitopes, different retrieval methods like proteinase K, cooking in different 
buffers with pH 6 or pH 9 and heating in the microwave, were tested. Different 
dilutions of the primary antibody as well as varied incubation times were used to find 
optimal staining procedure. When tested over night the slides were incubated at 4C 
degrees in a fridge. Endogenous peroxidase and alkaline phosphatase were inhibited 
prior to incubation with the primary antibody. Detection systems based on 
horseradish peroxidase (HRP) in combination with 3,3'-diaminobenzidine (DAB). 
Final counterstaining with hematoxylin was applied on all antibodies.  
 
 Evaluation of staining methods and assessment of markers 
Immunohistochemical staining was evaluated in a semi quantitative manner as 
described in chapter 3.9. MP and OS evaluated optimal primary antibody incubation 
time with a double light microscope. All evaluations of staining were done with the 
same double light microscope. For VEGF-A, VEGFR2, PDGFβR and HSP27 
assessments were done by MP and OS. For IL6, IL6Rα, IL6ST and JAG1 assessment 
were first rated by MP and all non-conclusive cases were discussed with OS.  
 
Because of limited amount of tumor tissue in some samples, there was not a complete 
set of staining in the different biomarkers (paper II, table 2).  
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Assessment of staining index (SI) was performed using both the intensity and the area 
of protein expression. The method evaluates the intratumor protein expression better 
than the staining intensity alone 234,235. The lack of standardized staining protocols 
and multiple methods of evaluation are important to consider when comparing with 
other reports  .  
 
 Analyses of blood  
ELISA is a simple and efficient assay method 237,238. In our work we used sandwich 
ELISA, reported to be 2-5 times more sensitive than other ELISAs 239.  
 
It is important to avoid or reduce analytic errors 239. To reduce pre-analytic errors, the 
samples were taken following a strict protocol. We stored the supernatant at -80 
Celsius. The patients were told to be fasting before taking samples. To reduce 
analytic errors, we used the same manufacture, the same type of plates for each 
antibody and the same experienced staff members. Post-analytic errors were reduced 
by not calculating the concentration using a curve expects program.  
 
The choice of sample type is important in the planning phase of the study. The 
sampling protocol must be standardized to make sure there is little variation in 
handling of samples. Advantages and disadvantages of additives in various tubes 
must be considered because they can be an issue in later analyses.  
 
The use of serum samples reduces this problem, but proteins can be bound by 
different cells during clotting. In our work, fibrin had to be removed in some samples.  
 
ELISA kits from different companies are pre-coated with different antibodies, which 
may result in different detection sensitivity and protein concentration 239. Sensitivity 
for binding a protein of interest may not be high enough, especially if the expected 
concentration is low. In single protein ELISA, reactivity of a kit with an antigen may 
be visually traceable and cross-reactivity therefore less relevant. Enough plasma is 
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needed to analyze one protein in duplicate and insufficient binding of a antigen to the 
antibody epitope can be problematic 239. 
 
 Health related Quality of life 
Our findings showed how higher baseline QoL symptom scores are prognostic for 
PFS and OS in treatment with sunitinib. This is in line with the earlier report by Cella 
et al. 123. In their report, however, a different QoL tool was used. Herrmann et al 
demonstrated by using EORTC QLQ-C30, that global QoL was prognostic for PFS 
125. Our study could not confirm this finding. In general, there were only small 
changes in QoL scores form baseline to 12 weeks. Herrmann et al. also showed a 
relatively small change in global QoL after 12 weeks 125. This could be due to the 
administration of sunitinib (4 weeks on/ 2 weeks off), with subsequent remission of 
eventual treatment induced symptoms. There are indications that long-term survivors 
might retain a good QoL over years, as described by Carmichael et al. 240.  
 
The QLQC30 form was not always given to the patient before information about CT 
scan. This may have biased the results of HRQoL data, because of information about 
disease status.  
 
 Statistics 
The sample size was calculated to show predictive value of sunitinib treatment in 
patients with metastatic ccRCC. In addition to the lack of a control group, our study 
has some weaknesses. First, the number of patients included is low and thereby the 
study lacks the significant power to detect minor differences in response rates 
between groups based on the biomarkers under investigation.  
 
Thus, our findings should be validated in an independent and larger cohort of 
patients. Still, our data strongly suggest that biomarkers associated with tumor 
immune responses might be important in patients treated with anti-VEGF therapy. 
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We used the Mann-Whitney U test to distinguish between responders and non-
responders. In clinical practice, it is necessary to use a cut-off definition on predictive 
markers.  
 
In this study, we focused on single candidate biomarkers based on our hypotheses, 
and not panels of multiple markers. Bonferroni testing or other test for multiple 
testing were unused for correction. The main reason was the small size. Perneger, a 
medical epidemiologist, discusses limitation of the test 241. He argues that quote; 
“Bonferroni adjustments follow the original logic of statistical tests as supports of 
repeated decisions, but they are of little help in determining what the data say in one 
particular study” 241. External validation is most important to control clinical validity.  
 
5.2 Discussion of results 
 Angiogenesis, inflammation and anti-angiogenic treatment in 
RCC 
In this translational study, we have investigated the predictive value of markers of 
anti-angiogenic treatment. Until recently, chemotherapy, palliative surgery and 
radiation therapy were the only treatment options for metastatic RCC, and primary 
therapy resistance, reduced quality of life and short survival were major challenges in 
this patient group. Currently, three major categories of systemic treatment exist for 
the largest subgroup of metastatic RCC, the ccRCC: cytokines and immune 
checkpoint inhibitors, anti-VEGF targeted drugs and mTOR inhibitors 242. The two 
latter of these new treatment options have emerged based on knowledge of the 
pathogenesis of ccRCC. The VHL tumor suppressor gene is lost or mutated in 60-
90% in sporadic cases 23 and is a major contributor to development of this cancer. 
Loss of VHL leads to a chronic stress response state in the cells trough high levels of 




In addition to being a potent angiogenic growth factor, VEGF plays a role in the local 
immune response in wounds and tumors by inducing accumulation of immature 
dendritic cells, myeloid-derived suppressor cells, regulatory T cells, as well as by 
inhibiting the migration of T lymphocytes to the tumor 80. RCC is regarded as highly 
immunogenic and angiogenic tumors, supporting VEGF as target for treatment. The 
VEGF receptor inhibitor sunitinib has been first line treatment for metastatic RCC 242, 
but a significant portion of the patients do not respond, and the search for good 
predictive markers of response has been disappointing. Whereas the focus in search 
for predictive markers has been on angiogenesis 136,243, markers of hypoxia 136,138,243, 
clinical markers 113,147,148, VHL mutation status 244 and single nucleotide 
polymorphisms (SNPs) 245,246, less focus has been on markers of immune responses.  
 
Recently, an inverse response relationship was reported for VEGF inhibitor treatment 
and immune checkpoint inhibitor treatment according to IMDC risk groups 142. New 
predictive biomarkers are needed to further optimize treatment for individual patients. 
The ongoing search for biomarkers to optimize VEGF inhibitor treatment in RCC has 
so far been unsuccessful in finding predictive biomarkers useful for clinical practice. 
In our work, we have presented results suggesting a predictive role of CRP, IL6 and 
IL6Rα 121,141,233. This might indicate the immunomodulating effect of anti-VEGF 
therapy plays an important role in treatment response in addition to the effect on 
angiogenesis.  
 
 Candidate markers of inflammation 
C-reactive protein (CRP) is an acute-phase protein that increases rapidly following 
IL6 secretion by macrophages and T-cells following infection, inflammation and 
cancer 79. CRP is a negative prognostic marker in cancer 247.  
 
Our results indicate that an inflammatory response, defined by high CRP is associated 
with poor response to sunitinib and poor prognosis in these patients. The response to 
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VEGF inhibition by sunitinib thus seems to be more pronounced in patients with a 
non-inflammatory state defined by normal CRP. Nevertheless, the significant 
association with response rates suggests CRP might be a useful marker, in addition to 
other clinical and biochemical features to consider prior to initiation of systemic 
treatment. 
 
In our material (paper I), we found normal CRP to be a possible predictive factor of 
response. Whereas 41% of the patients with normal CRP at baseline experienced an 
objective response, this was the case for only 5% of patients with CRP levels at 
baseline above normal. CRP was also associated with PFS and OS supporting its role 
as a prognostic marker as well, and this is in line with previous reports 144,248,249. In a 
study by Fujita et al normal level of CRP at baseline was an independent predictive 
marker of response in multivariate analysis 144. In a retrospective study of 200 
patients treated with sunitinib, 61% of patients with normal CRP responded versus 
32% of patients with elevated CRP 250. In our study, CRP was correlated to several 
factors including other markers of systemic inflammation like high platelet counts 
and anemia as well as tumor load and performance status.  
 
Interleukin-6 (IL6) is an important tumor-promoting protein associated with stress 
responses, inflammation and angiogenesis and has a role in the regulation of 
metabolic, regenerative and neural processes 67,71,129,130. Through its major 
downstream target STAT3 several tumor promoting pathways are activated, including 
HIF1α and increased VEGF activity 67. As a response to cellular stress, IL6 activation 
of the transcription factor STAT3 drives angiogenesis by inducing expression of 
VEGF and fibroblast growth factor by tumor cells, and thereby supports 
vascularization required for tumor growth and metastasis 68,69. Our results are in 
support of previous reports indicating that high levels of inflammation-associated 
cytokines are negative for the outcome of treatment 130.  
 
IL6 signals in cells via classic (membrane-bound) and trans-signaling (soluble) 
pathways 251,252. The trans-signaling pathway is considered to be pro-inflammatory 
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253. Elevated IL6 has been associated with poor survival in RCC and resistance to 
rTKI treatment 127,131-133. Tumor cells produce IL6 in response to cellular stress like 
hypoxia, and enhanced levels of IL6 is associated with increased tumor cell invasion 
71,254. The prognostic information of IL6 and IL6Rα is well known 71,128. A predictive 
value of IL6 levels has also been reported for response to immune checkpoint 
inhibitors 255.  
 
Kwon et.al. found a stimulating effect of elevated IL6 on endothelial cells, which 
might represent a resistance mechanism to anti-VEGF therapy 78. Elevated levels of 
IL6 among patients with poor response were also found in a recent work of Mizuno, 
investigating angiogenic, inflammatory and immunologic markers of sunitinib 
treatment in 56 patients with metastatic RCC 133. However, they did not include 
patients with poor IMDC risk score. Our findings may therefore show that we can 
include this group as well. Tran et.al. found opposite results, with a significant 
increase in PFS in patients treated with pazopanib versus placebo, in patients with 
high serum IL6 135.  
 
Tissue and serum levels of IL6 are elevated in RCC, and high levels of IL6 have been 
associated with elevated CRP and poor survival in RCC patients 126,127,131,256. Being 
closely correlated to IL6 expression, increased CRP levels might therefore be a 
surrogate marker of IL6 driven disease, again being associated with expression of 
multiple angiogenic factors 257, thus less responsive to specific anti-VEGF treatment 
like sunitinib.  
 
In paper II, we found that low tumor cell expression of IL6Rα was significantly 
associated with improved OR and that low tumor cell expression of IL6 was 
significantly associated with improved PFS and OS to sunitinib 258. Blay et al. 
previously showed that a higher IL6 level correlated with increased concentration of 
CRP 256. In our study, IL6 was not significantly associated with CRP. 
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Absent/low expression of both IL6 and IL6Rα was beneficial to treatment outcome, 
although not significantly associated with response rates, but the group with low 
expression of IL6 had almost a doubling of PFS compared to median/high expression. 
In line with previous reports, this suggests IL6 expression has prognostic value 
independent of the treatment given 126,127.  
 
Fu et.al. found that IL6 and IL6Rα co-expression might be an independent early-stage 
immunologic prognostic factor for patients with organ-confined ccRCC 134. In paper 
III, low baseline level of pIL6 was significantly associated with clinical benefit of 
sunitinib treatment and improved PFS. Our results are in support of previous reports 
indicating that high levels of inflammation-associated cytokines are detrimental for 
the outcome of sunitinib treatment 130.  
 
The interleukin 6 receptor α (IL6Rα) binds to the interleukin 6 signal transducer 
(IL6ST), also known as glycoprotein 130 (gp130) protein receptor to transduce the 
signal. Dysregulation of the cytokine IL6 and its receptor is involved in the 
pathogenesis of several diseases, like autoimmune conditions and cancer 259. The 
membrane-bound IL6Rα is found on hepatocytes and different leukocytes 260. In 
trans-signaling, soluble IL6 binds to soluble IL6Rα and the complex binds to cells 
expressing IL6ST 261. Soluble IL6ST is also detected in the blood and has been shown 
as an inhibitor of IL6 trans-signaling 262. The prognostic value of IL6Rα expression 
has previously been presented, where Costes et al. found a significant association 
between IL6Rα expression and OS in patients with primary RCC tumors 128. 
 
In paper II, we found that low expression of IL6Rα may predict response to rTKI 
treatment. IL6Rα was expressed in all cases, and low expression of IL6Rα was 
significantly associated with OR to sunitinib treatment 233. Only 10% of patients 
showing increased expression of IL6Rα responded, suggesting that high IL6Rα 
expression might represent an essential mechanism of resistance to anti-VEGF 
therapy in ccRCC.  
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When correlating IL6Rα to the other biomarkers investigated, we found that 
median/high expression of IL6Rα was significantly associated with median/high 
expression of HSP27. Both IL6 and HSP27 signaling constitute cellular stress 
responses and increase the level of VEGF through activation of STAT3 69,263. 
Schuster et al. found that high HSP27 expression in melanoma metastases predicts 
response to anti-VEGF treatment 264. In this work, we did not detect an association 
between HSP27 expression and treatment response.  
 
In paper III, the baseline level of soluble IL6Rα in plasma was not significantly 
associated with response variables, though low pIL6Rα tended to be associated with 
improved OS. In paper II, low tumor cell expression of IL6Rα was beneficial for 
treatment response. The complexity of membranous and soluble IL6Rα is thoroughly 
discussed in several reviews 68,71,265.  
 
Membranous IL6ST is universal expressed in human tissue 266. IL6ST and IL6Rα 
form a buffer for pIL6 in the blood, and is purposed to represent a mechanism by 
which the organism defends itself from unspecific overstimulation by IL6 trans-
signaling 265. Even though the range of pIL6ST in our cohort was lower compared to 
a normal cohort, the group pIL6ST below median level had worse OS (paper III, 
table 3). This is in line with previous findings 127. This may support the idea of a 
well-functioning buffer to protect against unspecific overstimulation by IL6-trans-
signaling 265. The cases with sunitinib induced reduction of pIL6Rα after two rounds 
of treatment had improved PFS. A reduction of pIL6Rα might be supported by the 
theory that trans-signaling pathways mediate cancer development 253,267. Our results 
suggest that this may be used as a marker of beneficial on-treatment response, and 
suggest a relation between IL6Rα in tumor cells and level of circulating pIL6Rα.  
 
Other findings  
The neutrophil-to-lymphocyte ratio (NLR) is also a marker of systemic inflammation 
in cancer patients and was found to add prognostic 82 and predictive 81 information in 
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RCC in retrospective studies. Like CRP, NLR is readily available in standard blood 
samples in an ordinary clinical setting. Our NLR counts were comparable to previous 
reports in other clinical datasets 81,82. Although significantly associated with CRP, we 
did not find a statistically significant association with sunitinib response or survival. 
The significant correlation with performance status and tumor load suggests that NLR 
is a nonspecific marker of disease burden.  
 
Treatment induced early hypertension (eHTN) was not significantly associated with 
treatment response in our dataset. In our patient population, the baseline blood 
pressure was slightly higher when compared with the clinical trial population studied 
by Rini et al 113, and 52% of our patients were hypertensive at baseline (paper I). 
Still, the number of patients recorded as having sunitinib induced eHTN after cycle 1 
and 2, using the same criteria, was nearly the same (~80%). eHTN at week 12 was 
associated with improved survival, but this is most likely because of the fact that the 
responders in the study stayed on treatment long enough to develop hypertension. 
Even if pharmacodynamically interesting, as eHTN occurs after sunitinib initiation it 
is not going to be an applicable predictive marker in the clinic.  
 
Jagged 1 (JAG1) is one of five Notch ligands. The Notch signaling pathway represent 
a regulator of tumor angiogenesis, stem cell self-renewal, cell fate determination, 
epithelial cell polarity/adhesion, cell division and apoptosis 268-271. In metastatic 
ccRCC, high JAG1 was associated with poor prognosis 272. In aggressive breast 
cancer cells, Sansone et.al. found that IL6 could stimulate Notch-3 dependent 
upregulation of JAG1 in an autocrine matter in response to hypoxic conditions 273. In 
our present cohort, the expression of JAG1 was unrelated to OR, but absent/low 
expression of IL6 was significantly associated to absent/low expression of JAG1. 
These JAG1 results may support a possible interaction of JAG1, Notch and IL6 273.  
 
Whereas VEGF-A was expressed in all tumors, we observed no association to 
response, in line with other studies 136,243. VEGF-A signals through VEGFR2 on 
endothelial cells to activate angiogenesis 274. Dornbush et al. found an association 
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between high expression of VEGFR2 and good treatment response 136, and Terakawa 
et al. also found high expression of VEGFR2 to be beneficial to sunitinib treatment 
137. In the last paper, the majority of patients was in the good prognostic group 
whereas in ours, the majority was in the poor prognostic group 121.  
 
PDGF receptors are key regulators of mesenchymal cells of the tumor 
microenvironment in several malignity’s 275. In cancers, an association between high 
stromal PDGFRβ expression or signaling and poor prognosis is reported 275. 
However, we did not detect an association to response in our present data.  
 
Our finding that higher baseline health related Quality of life (HRQoL) symptoms 
score was prognostic for PFS and OS in treatment with sunitinib is in line with the 
earlier report by Cella et al.123. In that report, however, a different QoL tool was used. 
Herrmann et al. demonstrated by using EORTC QLQ-C30, that “global QoL” was 
prognostic for PFS 125. Our study did not confirm this finding. In general, there were 
only small changes in HRQoL scores form baseline to 12 weeks. Herrmann et al. also 
showed a relatively small change in the different HRQoL scales after 12 weeks 125. 
This could be due to the administration of sunitinib (4 weeks on/2 weeks off), with 
subsequent remission of eventual treatment induced symptoms. There are indications 
long-term survivors might retain a good HRQoL over years, as described by 
Carmichael et al. 240.  
 
 Challenges 
A major challenge in studies exploring predictive markers of treatment response in 
clinical data-sets is the fact that most of the candidate predictive markers are 
prognostic as well, thus significantly correlated with PFS and OS independent of the 
treatment given. Combined predictive and prognostic markers are best evaluated in 
two-arm trials. In single arm trials like ours, response rates according to RECIST are 
superior to PFS and OS as primary end-point when assessing predictive markers of 
treatment response 276. Many biomarker studies in metastatic RCC have been 
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performed retrospectively in data-sets from large clinical trials, and these patients are 
frequently positively selected and do not optimally reflect the normal patient 
population. The strength of our study is the prospective design and the “Real-World” 
patient population enrolled, reflecting a normal clinical setting. When compared with 
large retrospective multicenter studies as well as smaller single-center studies, the 
majority of our patients were in the poor risk group according to IMDC criteria. 
Whereas the portion of poor-risk patients varies between 18 % and 33 % in 
comparable studies 81,114,144, 41.3% of our patients belonged to this group. In addition, 
all patients were in confirmed clinical and/or radiological progression at the time of 
inclusion. Accordingly, patients with very slow progression or stable metastases were 
observed without systemic treatment and screened for inclusion in the study only 
after confirmed disease progression. For this reason, PFS and OS were lower in our 
patients in comparison with clinical phase III trials. Compared with the adverse 
events reported in clinical trials 171, the frequency of toxicity from sunitinib in 
metastatic RCC recorded in our study was similar, or somewhat less frequent. 
Especially, the hematological toxicity including anemia, neutropenia, 
thrombocytopenia and lymphopenia were less frequent in our trial, although using the 
same criteria (CTCAE v. 3.0). The most likely explanation for this discrepancy is we 
assessed adverse events, including laboratory, every 6 weeks, where most of the 
patients were off the drug in the 4+2 weeks cycle. 
  
In our study, the number of patients included is low and thereby the study is not 
sufficiently powered to detect minor differences in response rates between groups 
based on the biomarkers under investigation. Thus, our finding should be validated in 
an independent and larger cohort of patients. Validation of a biomarker is very 
important and many study fails in the validation process. A biomarker must have both 
analytical validity and clinical validity 277. Analytic validity is how the test is 
accurate, reproducible and reliable 277. Clinical validity is how the biomarker can 
divide a population into two separate groups with different clinical outcomes 277. To 
introduce a cancer biomarker test into standard clinical management, it must also 
demonstrate “clinical utility” 277. Clinical utility is defined as “the test’s ability to 
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significantly improve measurable clinical outcomes, and its usefulness and added 
value to patient management decision making compared with current management 
without testing” 277.  
 
Second, CRP and NLR are non-specific markers of inflammation and angiogenesis, 
and further studies are required to identify the key regulators controlling the systemic 
responses to metastatic disease. Third, the reproducibility of the quantification of 
protein expression used in this study also needs to be validated in a separate patient 
cohort.  
 
Still, our data strongly suggest that biomarkers associated with tumor immune 
responses might be important in patients treated with anti-VEGF therapy. 
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6. Conclusions 
In conclusion, in this prospective study of sunitinib in patients with metastatic ccRCC 
we found that patients with low expression of inflammation markers responded better 
on sunitinib.  
 
In paper I, we found CRP was significantly associated with response rates and might 
serve as guidance in the selection of optimal treatment.  
 
In paper II, we found that reduced expression of IL6Rα was significantly associated 
with improved objective response to sunitinib. Expression of IL6Rα might be a 
potential predictive biomarker of response to guide treatment of patients with 
metastatic ccRCC. We also found low expression levels of the IL6 ligand in tumor 
cells provided significant positive prognostic information.   
 
In paper III, we found that low level of plasma IL6 is a positive predictive marker of 
improved response to sunitinib.   
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7. Future perspectives 
To find predictive markers of anti-angiogenic therapy is difficult. The anti-angiogenic 
receptor tyrosine kinase inhibitor sunitinib is still first line treatment in metastatic 
RCC in Norway. Today there are no established predictive markers in clinical use. 
Inflammation is an important part of cancer. In our study, we found that low level of 
IL6 in plasma may predict treatment response of sunitinib and guide clinicians in 
making better treatment plans in RCC. The results suggest that up-regulation of 
plasma IL6 might represent an important mechanism of resistance. If validated in 
independent patient cohorts, the biomarker can easily be implicated into routine 
practice for a low cost using ELISA. Baseline measurement of this biomarker might 
guide clinical decision making in treatment of patients with metastatic ccRCC.  
 
Sunitinib is overtaken by immune checkpoint inhibitors in favorable risk group 38, but 
many patients do still not have curation. It is therefore necessary to find the patients 
that will have a benefit of anti-angiogenic treatment like sunitinib or other targeted 
therapy. A next step may be to test treatment that bypasses the mechanism of 
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Abstract
Background: Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell
carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision
making.
Methods: In the present study we investigated the predictive value of standard serum markers as well as clinical
markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in
an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a
prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1
were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers
with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life
was recorded.
Results: Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1
patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive
disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01).
Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively).
Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival.
Conclusion: Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of
survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small
sample size, our results need to be confirmed in larger studies.
Background
The frequent inactivation of the Von Hippel Lindau
(VHL) gene in clear cell renal cell carcinoma, leading to
increased levels of hypoxia inducible factor 1 (HIF1) and
vascular endothelial growth factor (VEGF), provides the
rationale for treatment with antiangiogenic receptor
tyrosine kinase (rTKI) inhibitors. Since the reporting of
the first positive clinical trial [1], showing an overall sur-
vival benefit from a rTKI, sunitinib has become mainstay
first line treatment for patients with metastatic renal cell
carcinoma (mRCC). Although objective response rates
are reported for around 50% of the patients, develop-
ment of resistance to the treatment is a major problem
[2]. Clearly, a subset of patients does not benefit from
treatment with sunitinib, and side effects are frequent.
Interestingly, hypertension is a common side effect of
angiogenesis inhibitors and has been associated with
improved treatment response [3]. In the research com-
munity, considerable effort has been made to identify
and validate predictive biomarkers of response to suniti-
nib treatment, but so far, no biomarkers have been
established as useful in clinical decision making and
treatment planning.
There is increasing evidence to support an important role
of systemic inflammation in development and progression
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of RCC [4], as recently substantiated by positive results
from a clinical trial with the PD-1 inhibitor nivolumab in
mRCC [5]. VEGF does not only stimulate tumor associated
angiogenesis, but also plays an important role in the local
immune response in wounds (physiologic) and tumors
(pathologic) by inducing accumulation of immature den-
dritic cells, myeloid-derived suppressor cells, regulatory T
cells, as well as by inhibiting the migration of T lympho-
cytes to the tumor [6]. Thus, it is relevant to also explore
biomarkers primarily associated with inflammatory re-
sponses in the search for predictive markers for response to
anti-VEGF therapy.
C-reactive protein (CRP) is an established biomarker
for systemic inflammation, available in most clinical
datasets, and provides prognostic information in several
cancers including RCC [7]. Another biomarker of in-
flammation, neutrophil-to-lymphocyte ratio (NLR), adds
prognostic information in RCC, and was recently sug-
gested as a predictive marker of response to sunitinib in
mRCC [8]. In the present trial we investigated the pre-
dictive value of serum markers, including CRP and NLR,
in an unselected prospective patient population treated
with sunitinib for mRCC. In addition, we report on tox-
icity and health related quality of life (HRQoL) data.
Methods
Patients and treatment
Between October 2007 and October 2014, a regional
cohort of 77 patients with mRCC was screened for in-
clusion in this prospective study at Haukeland University
Hospital, Bergen, Norway. Forty-six patients were enrolled
after signing the informed consent sheet (CONSORT Flow
Diagram, Additional file 1: Fig. S1). Inclusion criteria in-
cluded: previously untreated metastatic or non-resectable
clear cell RCC, WHO performance state 0–2, no known
brain metastases, evaluable tumor lesions according to
RECIST (version 1.1) and no significant comorbidity or
laboratory abnormalities. See Additional file 2: Table S1
for all inclusion criteria. Sunitinib was administered
50 mg/day on schedule 4 weeks on/ two weeks off. Pa-
tients continued on treatment until disease progression,
significant toxicity or consent withdrawal. Data was
collected from the hospital records and included
demographics, treatment modifications, adverse events,
radiologic response data and survival. Data cut-off date
was July 31 2015.
The main objective of this study was to identify and
evaluate the predictive value of candidate markers
readily available in a standard clinical setting, in mRCC
patients treated with sunitinib. Candidate markers in-
cluded early hypertension (eHTN), IMDC risk groups,
baseline neutrophil to lymphocyte ratio (NLR), baseline
CRP and baseline EORTC QoL symptom scale. Response
rates according to RECIST 1.1 were used as primary
endpoint. Secondary objectives were to evaluate prognos-
tic value of the candidate markers with regard to progres-
sion free survival (PFS) and overall survival (OS). In
addition, toxicity rates and HRQoL was recorded.
Assessment of response, adverse events and quality of life
The primary endpoint was objective response (OR) de-
fined as complete response (CR) or partial response (PR)
according to RECIST v.1.1 as well as clinical benefit
(CB) defined as CR + PR and including stable disease
(SD) for more than 6 months. Disease stabilization is
considered beneficial to patients experiencing progres-
sion at the time of inclusion and CB is frequently in-
cluded as an additional statistical endpoint in trials
investigating antiangiogenic drugs in which therapeutic
activity and clinical benefit are present, even in the ab-
sence of radiological tumor shrinkage [9]. Importantly,
all patients were in clinical and/or radiological progres-
sion at the time of inclusion. OR and CB were calculated
on the basis of investigator assessment. Response evalu-
ation by CT-scan or MRI was performed every 12 weeks.
Patients with clinically evident disease progression or
death due to mRCC before first radiological progression
were recorded as progressive disease (PD). Best overall
response (BOR), recorded as change in size of target le-
sion, was not available in these patients. PFS was defined
as the time from treatment initiation until disease pro-
gression according to RECIST v.1.1. OS was defined as
the time from enrollment until death of any cause.
Standard blood samples, including CRP and neutro-
phil/lymphocyte counts, were taken at treatment initi-
ation and every 6 weeks during treatment. Adverse
events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse
events, version 3.0 (CTCAE v.3.0), and were recorded at
each 6-week cycle. Early hypertension (eHTN) was par-
ticularly evaluated for its potential role as a predictive
marker for treatment response. We recorded eHTN in
two different ways. First, we defined eHTN as either
maximum post-baseline systolic blood pressure (SBP)
≥140 mmHg or maximum post-baseline diastolic blood
pressure (DBP) ≥90 mmHg recorded at week 6 and week
12 [3]. Second, we recorded eHTN as HTN ≥ grade 1
defined by CTCAE v.3.0 at week 6 and week 12. All
other adverse events were recorded every six weeks
throughout the entire treatment period. Patients that
stopped treatment due to toxicity before 1st tumor re-
sponse evaluation at week 12 were not included in the
analyses of response rates or PFS, but were included in
the analyses of OS.
HRQoL was assessed by a validated Norwegian version
of the questionnaire of the European Organization for
Research and Treatment of Cancer (EORTC QLQ-C30
v.3.0) at baseline and every 12 weeks during treatment.
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The QLQ-C30 contains a global health/QoL scale, five
functional scales (physical, role, cognitive, emotional,
and social), three symptom scales (fatigue, pain, and
nausea/vomiting) and six single items (dyspnoea, insom-
nia, anorexia, constipation, diarrhoea, and financial diffi-
culties). The answers are given according to a 4-point
Likert format, with the exception of questions about
general health and quality of life, which are given ac-
cording to a 7-point Likert format. Scores was calculated
as described in the EORTC QLQ-C30 Scoring manual
(3rd edition) [10]. The C 30 functional scales and the
global scale were transformed so that 100% indicates
best function and 0% least function of the individual
QoL index, whereas the C30 symptom scales were trans-
formed so that 0% indicates the least and 100% the most
symptoms. We compared the upper quartile with the
lower 3 quartiles for the symptom sum score and the
lower quartile with the upper 3 quartiles for the func-
tional sum score and global health/QoL score.
Statistical analyses
The Mann-Whitney U test was used to compare the dis-
tribution of continuous variables between two groups
such as responders and non-responders. Comparisons
between categorical variables were performed by using
the Fisher’s exact test. Spearman’s rank correlation coef-
ficient was used to test correlations between variables of
interest. Logistic regression analysis was used to test the
relative importance of predictive factors for sunitinib
response. Cronbach’s α was used to estimate the reliabi-
lity of the global health score and the functional/symp-
tomatic scores made up of more than one question.
Kaplan-Meier estimates were applied for time-to-event
endpoints such as PFS and OS, and log rank-test was ap-
plied for testing of differences between groups. Sample
size calculations were based on a difference in response
rate of 40% (i.e. 10% and 50%) between groups identified
by the candidate markers. Thirty-eight patients were
needed to achieve a power of 80% with an α-value of
0.05. All p-values are two-sided. Statistical investigation
were done using IBM SPSS Statistics version 22.
Results
Patient population and treatment efficacy
The characteristics of the 46 patients enrolled in the
study are presented in Table 1. In our cohort the median
age was 63.1 (range 41.1–84.0). By July 31st, 2015 the
median follow up time was 13.8 months (range 1.8–
83.9). Twenty-six patients had prior removal of the pri-
mary tumor, twenty-four by radical and 2 by partial
nephrectomy. Six patients had resection of bone metas-
tasis, eight patients had resection of other metastasis,
one patient had gamma knife radiosurgery of brain me-
tastasis and two patients had radiation therapy against
bone metastasis prior to sunitinib treatment. Median
time on treatment was 5.7 months (range 0.5–63.0). Me-
dian time from first diagnosis of renal cell carcinoma to
treatment was 3.2 months (range 0.3–124). Median time
to treatment from diagnosis of metastasis was 1.4 months
(range 0.3–66.5).
Table 1 Baseline Patients Characteristics




Sex - No. (%)
Male 29 (63.0)
Female 17 (37.0)










Lymph nodes 28 (60.9)
Number of disease sites - No. (%)
1 10 (21.7)
2 11 (23.9)
≥ 3 25 (54.3)
Hypertension before treatment - No. (%)
Yes 24 (52.2)
No 22 (47.8)





Time from initial diagnosis - No. (%)
≤ 12 months 33 (71.7)
> 12 months 13 (28.3)
Prior removal of primary tumor - No. (%)
Radical nephrectomy 24 (52.2)
Partial nephrectomy 2 (4.3)
No 20 (43.5)
Abbreviations: WHO World Health Organisation, IMDC International Metastatic
Renal Cell Carcinoma Database Consortium
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By July 31 2015, median progression free survival
(PFS) was 9.1 months (range 0.5–57.3) and median over-
all survival (OS) was 15.4 months (range 1.8–83.9). At
data cut-off, 9 patients were still alive, and six patients
were still on sunitinib treatment without signs of
progression. Twenty-three patients started second line
systemic treatment. We observed 1 complete response
(CR), 7 partial responses (PR) and 18 patients had stable
disease (SD) ≥ 6 months. Twelve patients showed
progressive disease (PD), of which 10 were con-
firmed by radiology and 2 were confirmed by clinical
progress before week 12. Eight patients stopped
treatment before week 12 and were recorded as non-
evaluable for response rates and PFS. Of these, six
were due to toxicity without evidence of disease pro-
gression, one patient due to appendicitis and one
protocol violation. Of interest, seven of these eight
patients were females.
Predictive value of pre-treatment clinical and biochemical
markers and survival analyses
The correlations between clinical, as well as biochemical
markers assessed ahead of treatment initiation and suni-
tinib response are given in Table 2. The association be-
tween clinical, as well as biochemical markers assessed
ahead of treatment initiation, PSF and OS is given in
Table 3.
C-reactive protein (CRP)
Median CRP at baseline was 17.0 mg/L, range 0–235 mg/L.
Seventeen of 37 patients evaluated for overall response had
normal CRP (≤10 mg/L). Normal CRP at baseline was sig-
nificantly associated with OR (CR + PR) (Fisher’s exact test,
p = 0.01) (Fig. 1). Seven/17 (41%) of patients with normal
CRP had an objective response to sunitinib, compared with
1/20 (5%) patients with elevated CRP had an objective re-
sponse. Logistic regression analysis was used to test the
relative importance of the candidate predictive factors
for sunitinib response(eHTN, IMDC risk groups, base-
line NLR, baseline CRP, baseline EORTC QoL symptom
scale). Only CRP level at baseline was an independent
predictive variable of response, with an odds ratio of
14.3 (p = 0.02) of not having an objective response if
CRP was above normal (10 mg/L). CRP at baseline was
significantly correlated with several other variables in-
cluding age, function sum score, symptom sum score,
performance status and tumor load (Additional file 3:
Table S2). Median PFS was significantly longer among
patients with normal CRP at baseline (median 14.7 vs
5.3 months, log rank p = 0.05). Similarly, an improved
OS was found in patients with normal CRP at base-
line (median 26.0 vs 12.1 months, log-rank p < 0.01)
(Fig. 2 a, b).
Neutrophil to lymphocyte ratio (NLR)
Twenty-two of 34 (64%) patients evaluated for response
and available NLR, had NLR ≤3 at baseline (median = 2.7,
range 1.0–7.9) and NLR at baseline was not significantly
correlated with OR or CB. Eighty-three % of patients
evaluated for response had NLR ≤3 at week 6 (me-
dian = 1.6, range 0.4–5.9) and this was not significantly
correlated to OR or CB. A shift from NLR >3 at baseline
to ≤3 at week 6 (n = 10) was not significantly associated
with OR or CB. Median PFS among patients with base-
line NLR ≤3 was significantly better than patients with
baseline NLR >3 (median 14.7 vs 6.7 months, log rank
p = 0.05). A borderline association was present between
baseline NLR ≤3 and OS (median 25.2 vs 13.2 months,
log-rank p = 0.06). High NLR at baseline was signifi-
cantly correlated with increased tumor load (r = 0.43,
p = 0.005, Spearman).
Treatment induced early hypertension (eHTN)
Applying the first definition of eHTN (SBP ≥140 or DBP
≥90 mmHg at week 6 and week 12) seventeen of 32 pa-
tients (53%) evaluated for response had eHTN after
week 6. Median SBP over DBP was 145 (range: 120–
170) mmHg over 89 (range: 60–170) mmHg, and was
not significantly associated to OR or CB. Using the same
definition at week 12, fifteen of 19 patients (79%) had
eHTN. Median SBP over DBP was 142 (range: 120–170)
mmHg over 88 (range: 65–107) mmHg, and was signifi-
cantly associated with improved CB, but not OR
(Fischer’s exact test p = 0.04 and p = 0.53, respectively)
(Table 2). The second definition (based on CTCAE v 3.0)
of eHTN was not significantly associated OR or CB (data
not presented). eHTN at week 12 was associated with
improved PFS and OS (Table 3). All seven patients with
increased blood pressure during the two first cycles used
anti-hypertensive drug(s) at baseline.
Risk scores
The distribution of IMDC risk score [11] is given in
Table 1. IMDC risk score was not significantly associated
with OR or CB. Good IMDC risk score versus inter-
mediate and poor was not significantly correlated to PFS
(median 20.4 vs 9.1 vs 8.4 months, log-rank p = 0.10),
but was significantly associated with OS (median 67.9 vs
12.7 vs 13.7 months, log-rank p = <0.01). We found
similar results for MSKCC risk score and WHO per-
formance status (PS) (data not presented).
Metastatic sites
The distribution of metastatic sites is given in Table 1.
There was no significant association between metastatic
site and response rates. Although present in only 3 pa-
tients, pleura metastasis was significantly associated with
reduced PFS (median 2.6 vs 9.1 months, log rank
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Table 2 Univariate analyses of clinical and biochemical markers in relation to response to sunitinib










Total 8(21) 30(79) 26(68) 12(32)
Age 0.69 0.73
< 63.1 4(17) 19(83) 15(65) 8(35)
≥ 63.1 4(27) 11(73) 11(73) 4(27)
Sex 0.17 0.45
Female 4(40) 6(60) 8(80) 2(20)
Male 4(14) 24(86) 18(64) 10(36)
Number of disease sites 0.71 0.31
≤ 2 3(18) 14(82) 10(59) 7(41)
> 2 5(24) 16(76) 16(76) 5(24)
Prior nephrectomy 0.26 0.73
Yes 6(29) 15(71) 15(71) 6(29)
No 2(12) 15(88) 11(65) 6(35)
Pretreatment hypertension6 0.70 0.30
Yes 5(26) 14(74) 15(79) 4(21)
No 3(16) 16(84) 11(58) 8(42)
Treatment induced eHTN7 ≤ week 6 1.00 0.70
Yes 4(23) 13(77) 13(76) 4(24)
No 4(27) 11(73) 10(67) 5(33)
Treatment induced eHTN8 ≤ week 12 0.53 0.04
Yes 5(33) 10(67) 13(87) 2(13)
No 0(0) 4(100) 1(25) 3(75)
IMDC risk 0.77 0.46
Good 2(29) 5(71) 6(86) 1(14)
Intermediate 3(25) 9(75) 9(75) 3(25)
Poor 3(18) 14(82) 10(59) 7(41)
NLR baseline ≤3 1.00 0.46
Yes 5(23) 17(77) 16(73) 6(27)
No 3(25) 9(75) 7(58) 5(42)
NLR week 6 ≤ 3 0.32 0.15
≤ 3 7(23) 23(77) 22(73) 8(27)
> 3 0(0) 6(100) 2(33) 4(67)
NLR shifted from >3 to ≤3 at week 6 1.00 0.06
Yes 2(25) 6(75) 6(75) 2(25)
No 0(0) 3(100) 0(100) 3(100)
NLR shifted from ≤3 to >3 at week 6 1.00 0.50
Yes 0(0) 2(100) 1(50) 1(50)
No 5(26) 14(74) 14(74) 5(26)
CRP ≤10 (mg/L) 0.01 0.09
Yes 7(41) 10(59) 14(82) 3(18)
No 1(5) 19(95) 11(55) 9(45)
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p = 0.05) and OS (median 10.8 vs 17.5 months, log-rank
p = 0.04). Presence of lung metastasis was significantly
associated with reduced OS (median 13.2 vs 48.2 months,
log-rank p = 0.04). Other metastatic sites (brain, bone,
liver or lymph nodes) were not significantly associated
with PFS or OS.
Toxicity
Adverse events occurring during treatment with suniti-
nib according to CTCAE v.3.0 are summarized in
Additional file 4: Table S3. The most common adverse
effects of lower grade (1 + 2) were nausea (52.2%),
anemia (47.8%), fatigue (45.7%) and diarrhea (39.1%).
The most common severe adverse effects (grade 3 + 4)
were hypertension (19.6%), fatigue (15.2%), low serum
platelets (15.2%), hand-foot skin reaction (10.9%) and
diarrhea (10.9%). We observed one grade 5 adverse ef-
fect (death due to appendicitis) probably not related to
sunitinib treatment.
Health related quality of life
The results of the HRQoL questionnaires at baseline
(n = 45) and at the first treatment evaluation (n = 28, after
12 weeks) are presented in Additional file 5: Table S4.
Only for “Fatigue”, there was a statistically significant
increase in the score during treatment compared with
the baseline value (p=0.041, Wilcoxon ranked signed
test). The Cronbach- α of the indices derived by more
than one question showed acceptable/good values
(0.74-0.89), except for “cognitive function” (0.30) and
“social functioning” (0.56). The Cronbach- α of the sum
scores of functional indexes (0.80) and symptom in-
dexes (0.79) were acceptable/good. In contrast to Glo-
bal health status/QoL and Functional scale, a Symptom
sum score below median was significantly associated to
improved CB (Fisher’s exact test, p = 0.02, Table 2). In-
vestigating symptom sum scores indicated that the
upper quartile had significantly worse OS (median 12.7
vs 25.2 months, log-rank p = 0.01) and PFS (median 2.9
vs 14.7 months, log-rank p = <0.01). No such difference
could be demonstrated for global health/QoL status or
functional sum score (data not shown).
Discussion
Until recently, palliative surgery, radiation therapy and
chemotherapy were the only treatment options for
metastatic RCC (mRCC), and primary therapy resist-
ance, reduced quality of life and short survival were
major challenges in this patient group. Currently, three
major categories of systemic treatment exist for the
largest subgroup of mRCC, the clear cell carcinomas: cy-
tokines and immune checkpoint inhibitors, anti VEGF
targeted drugs and mTOR inhibitors [12]. The two latter
of these new treatment options have emerged based on
recent knowledge of the pathogenesis of clear cell renal
cancer. The von Hippel-Lindau (VHL) tumor suppressor
gene is lost or mutated in 60–90% in sporadic cases [13]
and is a major contributor to development of this cancer.
Loss of VHL leads to a chronic stress response state in the
cells trough high levels of HIF1-α, a transcription factor
for a number of stress response proteins, including vas-
cular endothelial growth factor (VEGF). In addition to
being a potent angiogenic growth factor, VEGF plays a
role in the local immune response in wounds and tu-
mors by inducing accumulation of immature dendritic
cells, myeloid-derived suppressor cells, regulatory T
cells, as well as by inhibiting the migration of T lym-
phocytes to the tumor [6]. Renal cell cancer is regarded
as highly immunogenic and angiogenic tumors, sup-
porting VEGF as a promising target for treatment. The
VEGF receptor inhibitor Sunitinib is currently first line
treatment for mRCC [12], but a significant portion of
the patients do not respond, and the search for good
predictive markers of response has been disappointing
so far. Whereas most focus in the search for predictive
markers has been on angiogenesis, less focus has been
on markers of immune responses. In the current study,
we evaluated readily available clinical and biochemical
markers, associated with systemic inflammation, for
their association with response to sunitinib.
Table 2 Univariate analyses of clinical and biochemical markers in relation to response to sunitinib (Continued)
EORTC QoL symptom scale at BL9 0.31 0.02
Upper quartile 0(0) 7(100) 2(29) 5(71)
Lower 3 quartiles 8(27) 22(73) 24(80) 6(20)
Abbreviations: IMDC International Metastatic Renal Cell Carcinoma Database Consortium, LDH Lactate dehydrogenase, ULN Upper limit of normal, LLN lower limit
of normal, NLR neutrophil/lymphocyte ratio, CRP C-reactive protein, BL baseline




5Clinical benefit (OR + SD)
6Defined as on anti-hypertensive treatment before initiation of sunitinib
7Defined as systolic blood pressure(SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg ≤ week 6
8Defined as ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg ≤ week 12
9Quality of Life
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Table 3 Survival analyses according to clinical and biochemical variables
Variable PFS1 OS2
Median 95% CI3 p-value4 Median 95% CI p-value
Age 0.29 0.47
< 63.1 8.7 6.2–11.2 17.5 5.5–29.4
≥ 63.1 20.4 3.2–37.7 15.0 12.4–17.6
Sex 0.03 0.87
Female NR - 12.7 7.3–18.2
Male 8.7 6.6–10.7 18.0 10.5–25.4
Number of disease sites 0.80 0.52
≤ 2 12.9 2.1–23.7 17.5 11.3–23.7
> 2 9.1 8.3–9.8 13.9 10.2–17.6
Prior nephrectomy 0.07 <0.01
Yes 14.7 5.9–23.5 26.0 20.1–31.8
No 8.7 3.1–14.3 10.8 4.5–17.0
Pretreatment hypertension 0.42 0.79
Yes 17.0 6.2–27.7 18.0 9.4–26.5
No 8.4 3.7–13.1 11.6 5.3–17.9
Treatment induced early hypertension5 at week 6 0.68 0.85
Yes 14.7 9.6–19.8 18.0 3.5–32.5
No 8.7 3.9–13.5 12.1 3.8–20.4
Treatment induced early hypertension5 at week 12 <0.01 <0.01
Yes 14.7 10.1–19.3 26.0 24.1–27.9
No 2.6 1.9–3.3 7.7 4.4–11.0
IMDC risk score 0.10 <0.01
Good 20.4 13.1–27.7 67.9 38.4–97.5
Intermediate 9.1 6.0–12.2 12.7 10.6–14.9
Poor 8.4 0–17.7 13.7 5.4–22.1
NLR baseline ≤3 0.05 0.06
Yes 14.7 8.8–20.6 25.2 10.6–39.8
No 6.7 2.0–11.4 13.2 10.3–16.1
NLR week 6 ≤ 3 0.09 <0.01
Yes 10.8 6.0–15.7 25.2 13.7–36.7
No 1.8 0.2–3.5 3.8 3.3–4.3
NLR shifted from >3 to ≤3 week 6 <0.01 <0.01
Yes 8.4 6.0–10.7 13.2 7.0–19.4
No 1.3 0.9–1.7 3.6 0.8–6.4
NLR shifted from ≤3 to >3 at week 6 0.75 0.16
Yes NR - 4.0 2.3–5.7
No 14.7 9.2–20.3 26.0 24.2–27.7
CRP 0.05 <0.01
≤ 10 (mg/L) 14.7 2.5–26.9 26.0 0.6–51.4
> 10 (mg/L) 5.3 0.9–9.8 12.1 8.8–15.5
EORTC QoL symptom scale at BL <0.01 0.01
Upper quartile 2.8 2.2–3.5 12.7 4.8–20.7
Lower 3 quartiles 14.7 4.6–24.8 25.2 12.7–37.7
Abbreviations: IMDC International Metastatic Renal Cell Carcinoma Database Consortium, LDH Lactate dehydrogenase, ULN Upper limit of normal, LLN lower limit of





5Defined as systolic blood pressure(SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg
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C-reactive protein (CRP) is an acute-phase protein that
increases rapidly following interleukin-6 secretion by mac-
rophages and T cells following infection, inflammation
and cancer [14]. CRP is a negative prognostic marker in
most cancers. In the present study we found normal CRP
to be a possible predictive factor of response. Whereas
41% of the patients with normal CRP at baseline experi-
enced an objective response, this was the case for only 5%
of patients with CRP levels at baseline above normal. CRP
was also associated with PFS and OS supporting its role as
a prognostic marker as well, and this is in line with previ-
ous reports [15–17]. Our finding supports the results of a
recent study by Fujita et al. where normal level of CRP at
baseline was an independent predictive marker of re-
sponse by multivariate analysis [15]. In a retrospective
study of 200 patients treated with sunitinib 61% of pa-
tients with normal CRP responded vs 32% of patients with
elevated CRP [18]. In our trial, CRP was correlated to sev-
eral factors including other markers of systemic inflamma-
tion such as high platelet counts, anemia as well as tumor
load and performance status. Thus, CRP might represent
a marker of disease burden identifying a patient subpopu-
lation with poor prognosis, less likely to respond. Never-
theless, the significant association with response rates
suggests that CRP might be a useful marker, in addition to
other clinical and biochemical features to consider prior
to initiation of systemic treatment. IL-6 is an important
tumor-promoting protein associated with stress responses,
inflammation and angiogenesis [19]. Through its major
downstream target STAT3 several tumor promoting path-
ways are activated, including HIF1-α and VEGF [19].
Moreover, IL6 have direct stimulating effect on endothe-
lial cells, and has been implicated in resistance to anti-
VEGF therapy [20]. Being closely correlated to IL6 expres-
sion, increased CRP levels might therefore be a surrogate
marker of IL6 driven disease, again being associated with
expression of multiple angiogenic factors [21], thus less re-
sponsive to specific anti-VEGF treatment like sunitinib.
Our results indicate that an inflammatory response,
defined by high CRP is associated with poor response to
sunitinib and poor prognosis in these patients. The effect
of sunitinib on inhibiting the angiogenesis supporting and
immunosuppressive effect of VEGF, thus seem to be more
pronounced in patients with a non-inflammatory state de-
fined by normal CRP.
The neutrophil-to-lymphocyte ratio (NLR) is also a
marker of systemic inflammation in cancer patients and
was found to add prognostic [22] and predictive [8] in-
formation in RCC in retrospective studies. Like CRP,
NLR is readily available in standard blood samples in a
regular clinical setting. Our NLR counts were compar-
able to what has been reported in other clinical datasets.
Fig. 1 Response rates as a function of baseline CRP levels. Patients
with a baseline CRP ≤ 10 mg/L (normal) showed an objective
response rate (CR + PR) of 41% whereas patients with elevated CRP
showed an objective response rate of 5%. CR, complete response;
PR, partial response; SD, stable disease; PD, progressive disease
Fig. 2 Kaplan-meier estimates of a) progression free survival (PFS) and b) overall survival (OS) grouped by CRP level. The normal CRP (≤ 10 mg/L)
cohort showed significantly improved PFS and OS compared with patients with elevated CRP
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Although significantly associated with CRP, we did not
find a statistically significant association with sunitinib
response or survival. The significant correlation with
performance status and tumor load suggests that NLR is
a nonspecific marker of disease burden. Still, due to rela-
tively small sample size and low statistical power, our
data must be interpreted carefully.
Treatment induced early hypertension (eHTN) was not
significantly associated with treatment response in our
dataset. In our patient population, the baseline blood pres-
sure was slightly higher when compared with the clinical
trial population studied by Rini et al. [3], and 52% of our
patients were hypertensive at baseline. Still, the number of
patients recorded as having sunitinib induced eHTN after
cycle 1 and 2, using the same criteria, was nearly the same
(~80%). eHTN at week 12 was associated with improved
survival, but this is most likely due to the fact that the re-
sponders in the study stayed on treatment long enough to
develop hypertension. Even if pharmacodynamically inter-
esting, as eHTN occurs after sunitinib initiation it is not
going to be an applicable predictive marker in the clinic.
Our finding that higher baseline HRQoL symptoms
score is prognostic for PFS and OS in treatment with Su-
nitinib is in line with the earlier report by Cella et al. [23].
In that report, however, a different QoL tool was used.
Herrmann et al. demonstrated by using EORTC QLQ-
C30, that “global QoL” was prognostic for PFS [24]. Our
study did not confirm this finding. In general, there were
only small changes in HRQoL scores form baseline to
12 weeks. Herrmann et al. also showed a relatively small
change in the different HRQoL scales after 12 weeks [24].
This could be due to the administration of Sunitinib
(4 weeks on/ 2 weeks off), with subsequent remission of
eventual treatment induced symptoms. There are indica-
tions that long-term survivors might retain a good
HRQoL over years, as described by Carmichael et al. [25].
A major challenge in studies exploring predictive
markers of treatment response in clinical data-sets is the
fact that most of the candidate predictive markers are
prognostic as well, thus significantly correlated with PFS
and OS independent of the treatment given. Combined
predictive and prognostic markers are best evaluated in
two-arm trials. In single arm trials such as ours, response
rates according to RECIST are superior to PFS and OS as
primary end-point when assessing predictive markers of
treatment response. Many biomarker studies in mRCC
have been performed retrospectively in data-sets from
large clinical trials, and these patients are frequently posi-
tively selected and do not optimally reflect the normal pa-
tient population. The strength of our study is the
prospective design and the “Real-World” patient popula-
tion enrolled, reflecting a normal clinical setting. When
compared with large retrospective multicenter studies as
well as smaller single-center studies, the majority of our
patients were in the poor risk group according to IMDC
criteria. Whereas the portion of poor-risk patients varies
between 18 and 33% in comparable studies [8, 11, 15],
46% of our patients belonged to this group. In addition, all
patients were in confirmed clinical and/or radiological
progression at the time of inclusion. Accordingly, patients
with very slow progression or stable metastases were ob-
served without systemic treatment and screened for inclu-
sion in the study only after confirmed disease progression.
In comparison with clinical phase III trials, PFS and OS
were lower in our patients. Compared with the adverse
events reported in clinical trials [26], the frequency of
toxicity from sunitinib in metastatic renal cell cancer re-
corded in our study was similar, or somewhat less fre-
quent. Especially, the hematological toxicity including
anemia, neutropenia, thrombocytopenia and lymphopenia
was less frequent in our trial, although using the same cri-
teria (CTCAE v. 3.0). The most likely explanation for this
discrepancy is that we assessed adverse events, including
laboratory, every 6 weeks, where most of the patients were
off the drug in the 4 + 2 weeks cycle.
In addition to the lack of a control group, our study has
some weaknesses. First, the number of patients included is
low and thereby the study lacks the significant power to
detect minor differences in response rates between groups
based on the biomarkers under investigation. Thus, our
finding should be validated in an independent and larger
cohort of patients. Second, CRP and NLR are non-specific
markers of inflammation and angiogenesis, and further
studies are required to identify the key regulators control-
ling the systemic responses to metastatic disease. In this
report, we focused on biomarkers available in standard
clinical blood samples routinely used in the clinic. Further
studies of candidate biomarkers in serum and plasma,
such as IL6 and IL8 are ongoing.
Conclusion
In conclusion, in this prospective study of sunitinib in
patients with mRCC we found that normal level of s-
CRP at baseline is significantly associated with improved
response rates and might serve as guidance in the selec-
tion of optimal treatment. Still, due to the relatively
small sample size and low statistical power, our results
need to be confirmed in larger studies.
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CONSORT 2010 Flow Diagram 
Assessed for eligibility (n= 77 ) 
Excluded  (n= 31  ) 
   Not meeting inclusion criteria (n= 31) 
   Declined to participate (n= 0) 
Analysed  (n= 46) 
 Excluded from analysis (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Allocated to sunitinib (n= 46) 
 Received allocated intervention (n= 46) 





Figure S1. 77 patients with metastatic renal cell carcinoma were screened for inclusion in the prospective 
clinical study. 46 patients were enrolled after signing the informed consent sheet. 31 patients did not meet 
the inclusion criteria; not clear cell mRCC: n= 17, WHO performance state >2: n= 6, brain metastasis: n= 
1, deep vein thrombosis: n= 1, no available biopsy: n= 2, impaired kidney function: n= 1, died during 
screening: n= 1, included in other study: n= 1.  

Table S1 – Inclusion criteria 
 
Metastatic or unresectable primary tumor of clear cell renal cell carcinoma 
WHO performance status 0-2 
Non-earlier cytokine treatment or other cancer treatment 
Radiation therapy against symptom given metastasis was possible, but not 
against lesion that we would like to evaluate response 
Non symptomatic brain metastasis, but radiation treated brain metastasis where 
corticosteroids is stopped is allowed 
>12 months since coronar bypass operation 
>18 years 
Not pregnant or breast feeding 
Clinically or radiographic measurable disease according to the RECIST 
>21 days since major surgery or damage 
>2 days since biopsy, FNAC or central venous catheter 
No ongoing grade 3 bleeding 
None of the following the last 12 months: 
  -Myocardial infarction 
  -Serious unstable angina pectoris 
  -Symptomatic heart failure (not including EF <50% or >20% reduction of EF    
   compared to beginning of treatment) 
  -Stroke including TIA 
  -Pulmonary embolism 
No other active malignant disease or not been treated for other cancers the last 
five years 
Uncontrolled hypertension 
Uncontrolled arrhythmia, especially prolonged QT-interval and bradycardias 
Laboratory values of: 
  -Granulocytes >1,5 x 10^9/L 
  -Platelets >100 x 10^9/L 
  -Bilirubin and <1,5x upper normal limit 
  -ASAT <2,5x upper normal limit 
  -ALAT <2,5x upper normal limit 
  -Creatinine <1.5x upper normal limit 
  -International Normalized Ratio (INR) < 1,5x upper normal limit   
No other compliance that could make the patient unsuitable to be included in a 
research protocol 
Written consent from every patient 
 
Abbrevations: WHO: World Health Organisation, RECIST: Response Evaluation 
Criteria in Solid Tumours, FNAC: Fine-Needle Aspiration Cytology, EF: 
Ejection Fraction, TIA: Transient Ischemic Attack, ASAT: aspartate 




Table S2. Correlations between CRP and other variables 
Variable CRP at baseline 
 Corr. coeff p-value1 
Age  -0.38 0.01 
IMDC risk score 0.61 <0.001 
NLR baseline 0.19 0.24 
Sum function score -0.38 0.01 
Sum symptom score 0.35 0.02 
S-Platelets 0.45 0.002 
S-Creatinine -0.53 <0.001 
S-Hemoglobin -0.59 <0.001 
S-Calcium 0.47 0.002 
S-Albumin -0.74 <0.001 
Tumor load 0.35 0.02 
 Median p-value2 
Sex   0.60 
  Male  17 mg/L  
  Female  16 mg/L  
WHO performance status  0.008 
  0  9 mg/L  
  1  78 mg/L  
1Spearman correlation. 2Mann Whitney test. Abbreviations: IMDC: 
International Metastatic Renal Cell Carcinoma Database Consortium. 




Table S3.  Adverse effects  
 Total Grade 1+2 Grade 3+4 
Laboratory    
  Hemoglobin 22(50.0) 22 (47.8) 1 (2.2) 
  Lymphopenia 4 (8.7) 2 (4.3) 2 (4.3) 
  Neutropenia 11 (23.9) 10 (21.7) 1 (2.2) 
  Platelets 14 (30.4) 7 (15.2) 7 (15.2) 
Cardiac    
  Hypertension 13 (28.3) 4 (8.7) 9 (19.6) 
  Hypertension (prior to 12 weeks) 7 (15.2) 2 (4.3) 5 (10.9) 
  Left ventricular systolic 
 dysfunction 
2 (4.3) 1 (2.2) 1 (2.2) 
Constitutional symptoms    
  Fatigue 28 (60.9) 21 (45.7) 7 (15.2) 
  Fever 3 (6.5) 2 (4.3) 1 (2.2) 
  Weight loss 3 (6.5) 3 (6.5) 0 (0) 
Dermatology/skin    
  Desquamation 9 (19.6)  9 (19.6) 0 (0) 
  Hand-foot skin reaction 17 (37.0) 12 (26.1) 5 (10.9) 
  Hypopigmentation 7 (15.2) 7 (15.2) 0 (0) 
  Rash (other) 5 (10.9) 5 (10.9) 0 (0) 
Endocrine    
  Thyroid function (high) 2 (4.3) 2 (4.3) 0 (0) 
  Thyroid function (low) 9 (19.6) 9 (19.6) 0 (0) 
Gastrointestinal    
  Anorexia 8 (17.4) 8 (17.4) 0 (0) 
  Constipation 4 (8.7) 4 (8.7) 0 (0) 
  Dehydration 3 (6.5) 2 (4.3) 1 (2.2) 
  Diarrhea 23 (0.5) 18 (39.1) 5 (10.9) 
  Dry mouth 2 (4.3) 2 (4.3) 0 (0) 
  Gingiva 2 (4.3) 2 (4.3) 0 (0) 
  Heartburn 8 (17.4) 6 (13.0) 2 (4.3) 
  Mucositis (clinical exam) 12 (26.1) 11 (23.9) 1 (2.2) 
  Mucositis (symptomatic/functional) 10 (21.7) 10 (21.7) 0 (0) 
  Nausea 24 (52.2) 24 (52.2) 0 (0) 
  Taste alteration (dysgeusia) 12 (26.1) 12 (26.1) 0 (0) 
  Vomiting 6 (13.0) 5 (10.9) 1 (2.2) 
Infection    
  Infections 7 (15.2)* 5 (10.9) 1 (2.2) 
Lymphatics    
  Periorbital edema 3 (6.5) 3 (6.5) 0 (0) 
Neurology    
  Dizziness 2 (4.3) 2 (4.3) 0 (0) 
  Mood alteration, depression 2 (4.3) 2 (4.3) 0 (0) 
  Neuropathy, motor 3 (6.5) 0 (0) 3 (6.5) 
Ocular/visual    
  Watery eye 3 (6.5) 3 (6.5) 0 (0) 
Pain    
  Gastrointestinal pain 12 (26.1) 11 (23.9) 1(2.2) 
  General pain 3 (6.5) 3 (6.5) 0 (0) 
  Headache 3 (6.5) 3 (6.5) 0 (0) 
  Musculoskeletal pain 11 (23.9) 8 (17.4) 3 (6.5) 
Pulmonary/upper respiration    
  Dyspnea 2 (4.3) 1 (2.2) 1 (2.2) 
Renal    
  Cystitis 2 (4.3) 2 (4.3) 0 (0) 
*One with Grade 5 (death due to appendicitis)   
 

Table S4.  The table shows the score (mean±SEM) of the global health status/ QoL, 
functional scales and symptom scales according to the EORTC QLQ-C30 scoring manual at 
baseline and after 12 weeks. The p-value is based on the non-parametric Wilcoxon signed 







    
Global health status / QoL 63±3 63±5 0.447 
Functional sum score 75±3 77±4 0.219 
Symptom sum score 20±3 22±4 0.166 
    
Functional Scales    
Physical function 73±3 74±5 0.977 
Role function 62±5 70±6 0.138 
Emotional function 77±3 81±4 0.415 
Cognitive function 89±2 88±3 0.064 
Social function 72±4 72±5 0.565 
    
Symptom Scales    
Fatigue 34±4 39±5 0.041* 
Nausea / vomiting  9±3  9±3 0.468 
Pain 32±5 32±5 0.705 
Dyspnoea 20±4 19±5 0.565 
Insomnia 22±4 24±6 0.554 
 Appetite loss 16±4 24±5 0.110 
Constipation 19±4 23±7 0.233 
Diarrhorea 15±3 21±5 0.364 
Financial problems 10±3 12±5 1.000 
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Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and anti-angiogenic
treatment is currently first line therapy for metastatic ccRCC (mccRCC). Response rates and duration of
response show considerable variation, and adverse events have a major influence on patient quality of life.
The need for predictive biomarkers to select responders to receptor tyrosine kinase inhibitors upfront is urgent.
We investigated the predictive value of immunohistochemical biomarkers associated with angiogenesis and
systemic inflammation in mccRCC. Forty-six patients with metastatic or non-resectable ccRCC treated with
sunitinib were included. Metastatic and/or primary tumour tissue was stained by immunohistochemistry for
selected markers related to angiogenesis [vascular endothelial growth factor A (VEGF-A), VEGF receptor 2
(VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and heat shock protein 27 (HSP27)] and
immune responses [Interleukin 6 receptor a (IL6Ra), interleukin-6 (IL6), and jagged1 (JAG1)]. The predictive
potential of the candidate markers was assessed by correlations with response rates (RECIST). In addition, pro-
gression free survival (PFS) and overall survival (OS) were analysed. Low tumour cell expression of IL6Ra was
significantly associated with improved response to sunitinib (Fisher’s exact test, p5 0.03), but not with PFS
or OS. Median/high expression of IL6Ra showed significant association with median/high expression of VEGF-
A and HSP27. Furthermore, low expression of IL6 was significantly associated with improved PFS, but not OS
or response rates. High expression of IL6 was significantly associated with high expression of JAG1, VEGF-A,
VEGFR2, and PDGFRb. Loss of tumour cell expression of IL6Ra in mccRCC patients treated with sunitinib pre-
dicts improved treatment response, and might represent a candidate predictive marker.
Keywords: clear cell renal cell carcinoma; sunitinib; interleukin 6; interleukin 6 receptor a; response rates; biomarker; anti-angiogenesis;
inflammation; immunohistochemistry; treatment efficacy
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Introduction
Clear cell renal cell carcinoma (ccRCC) is known to
be an immunogenic cancer [1]. Recently, nivolumab,
an immune checkpoint inhibitor, was shown to
improve overall survival (OS) in second line treat-
ment of metastatic disease [2]. Immunotherapy, such
as interferon and interleukin-2 therapy, was the only
treatment choice up until 2007 when anti-angiogenic
receptor tyrosine kinase inhibitors (rTKI) showed
superior efficacy [3]. rTKIs are currently first line
treatment options for metastatic disease. Still,
response rates and duration of response show consid-
erable variation among patients, and adverse events
have a major influence on quality of life [4]. Despite
scientific efforts to identify clinically useful
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predictive markers of response to anti-angiogenic
treatment, no such indicators have currently been
successful. Among many, the focus has been on
angiogenesis markers [5,6], markers of hypoxia
[5–7], clinical markers [8–10], VHL mutation status
[11], and single nucleotide polymorphisms [12,13],
but immune response-related markers are less
studied.
Vascular endothelial growth factor (VEGF) is the
most important mediator of tumour-associated angio-
genesis in renal cell carcinoma (RCC), and VEGF
receptor 2 (VEGFR2) is the main target of sunitinib.
Some reports suggest a role of systemic inflammation
in development and progression of RCC [1,14,15].
Along with a stimulating effect on tumour-associated
angiogenesis, VEGF also plays an important role in
the local immune response during wound healing as
well as in tumours by inducing accumulation of
immature dendritic cells, myeloid-derived suppressor
cells, regulatory T cells, and VEGF inhibits the
migration of T lymphocytes to the tumour [16].
In a recent study, we investigated the role of sys-
temic inflammation in metastatic ccRCC (mccRCC)
treated with sunitinib [4]. We found a significant cor-
relation between low serum C-reactive protein (CRP)
and objective response (OR). CRP is a relevant bio-
marker for systemic inflammation [17]. Tissue and
serum levels of interleukin-6 (IL6) are elevated in
RCC, and high levels of IL6 are associated with ele-
vated CRP in RCC patients [18,19]. IL6 has a role in
inflammation, infection responses, and the regulation
of metabolic, regenerative, and neural processes
[20–23]. In RCC, IL6 is secreted when cells are
exposed to hypoxia, and enhanced levels of IL6
result in RCC cell invasion [23,24]. IL6 has also
been shown to be closely related to HIF-1a as well
as increased VEGF activity [25]. IL6 signals in cells
via classic (membrane-bound) and trans-signalling
(soluble) pathways [26,27]. Interleukin 6 receptor a
(IL6Ra) binds to the gp130 protein receptor to trans-
duce the signal. Membrane-bound IL6Ra is found on
hepatocytes and different leukocytes [28]. In trans-
signalling, soluble IL6 binds to soluble IL6R and the
complex binds to cells expressing gp130 [29]. Taken-
awa et al have previously shown the presence of
IL6Ra on RCC cells [18] and Costes et al reported a
prognostic value of IL6 and IL6R in primary RCC
[30].
Another important signalling system and regulator
of tumour angiogenesis, stem cell self-renewal, epi-
thelial cell polarity, cell division, and apoptosis is the
Notch signalling pathway [31–34]. Thus, IL6 might
trigger a potential autocrine or paracrine Notch-3/
jagged1 (JAG1) loop to boost stem/progenitor self-
renewal in the mammary gland [35].
Here, we enrolled patients with mccRCC treated
with the VEGFR inhibitor sunitinib in a prospective
clinical study, and analysed an expanded panel of
candidate predictive biomarkers related to VEGF




Forty-six patients with mccRCC were enrolled in an
open-label, single-arm phase II study at Haukeland
University Hospital, Norway. Between 2007 and
2015, mccRCC patients with radiologically con-
firmed progressive disease were treated with sunitinib
50 mg/day on schedule 4 weeks on/two weeks off
until disease progression, significant toxicity, or con-
sent withdrawal. Study design, inclusion criteria, and
clinical response data were reported earlier [4]. In
summary, we observed 1 complete response (CR), 7
partial responses (PR), and 18 patients with stable
disease (SD) 6 months. Twelve patients showed
progressive disease (PD). Eight patients stopped
treatment before week 12 and were recorded as non-
evaluable for response rates and progression free sur-
vival (PFS). Thus, 38 patients were available for
response evaluation. Treatment response was
recorded according to RECIST 1.1 and the frequency
of OR (CR1 PR) was used as primary endpoint. The
evaluation of the prognostic value of the biomarkers
concerning PFS and OS were secondary endpoints.
Clinical information is provided in Table 1.
Ethics
The study followed the ethical principles of the Dec-
laration of Helsinki and the International Conference
on Harmonization of Good Clinical Practice. The
protocol was approved by the Regional Ethics Com-
mittee (REK number 080/07 and REK number 78/05)
and the Norwegian Medicines Agency. All participat-
ing patients provided signed informed consent before
enrolment.
Tissue samples
Tumour tissue was available in 45/46 (97.8%)
patients in total. The most recent biopsy, the meta-
static lesion (n5 29), or the non-resectable primary
tumour diagnosed closest to the date of clinical trial
inclusion (n5 12), was selected for further analysis if
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several lesions were available. In addition, protein
expression of the candidate markers was analysed in
primary tumours alone (n5 41). All results in this
paper refer to the most recent biopsy unless other-
wise specified. All metastases and primary ccRCCs
were reclassified by an experienced pathologist based
on haematoxylin and eosin-stained sections (LB).
Immunohistochemistry (IHC)
Tissue sections (4–5 mm) were stained with primary
antibodies for interleukin-6 receptor a (IL6Ra), IL6,
JAG1, vascular endothelial growth factor A (VEGF-
A), VEGFR2, platelet-derived growth factor receptor
b (PDGFRb), and heat shock protein 27 (HSP27).
Slides were deparaffinized in xylene and rehydrated
followed by antigen retrieval in a microwave oven.
Endogenous peroxidase and alkaline phosphatase
were blocked before incubation with the primary
antibody followed by incubation with the appropriate
visualization kit. Details are provided in supplemen-
tary material, Table S1. For negative controls, pri-
mary antibodies were omitted or specific blocking
peptides for HSP27 and VEGF-A were used. Tissues
from different cancer types were used as positive
controls. For JAG1, endothelial cells were used as
positive internal control.
Evaluation of tissue staining results
All sections were screened at 340 and 3100 total
magnifications to map areas of cancer tissue and
normal tissue. Further, with high power magnification
(3200 or 3400), staining intensity and the propor-
tion of positive tumour cells were recorded using a
semi-quantitative grading. Staining intensity was
defined as absent (0), weak (1), moderate (2), or
strong (3). The proportion was rated as ‘no positive
tumour cells’(0), ‘less than 10% positive tumour
cells’(1), ‘10–50% positive tumour cells’(2), or ‘more
than 50% positive tumour cells’(3). The staining
index (SI) is the product of intensity and proportion
(range 0–9) [36]. SI was used to quantify cytoplasmic
staining of IL6Ra, IL6, JAG1, VEGF-A, VEGFR2,
PDGFRb, and HSP27. Cases were categorized into
groups (absent/low versus median/high protein
expression) based on the SI distribution for each bio-
marker under investigation. Thus, cut-points were set
to: IL6Ra low (SI5 1–3) versus median/high
(SI5 4–9); IL6 absent/low (SI5 0–2) versus median/
high (SI5 3–9); JAG1 absent/low (SI5 0–2) versus
median/high (SI5 3–9); VEGF-A low (SI5 1–3) ver-
sus median/high (SI5 4–9); VEGFR2 absent/low
(SI5 0–2) versus median/high (SI5 3–9); PDGFRb
absent/low (SI5 0–1 versus median/high (SI5 2–9);
and HSP27 low (SI5 1–3) versus median/high
(SI5 4–9). In addition, protein expression in tumour-
associated endothelial cells was graded based on
staining intensity (0–3) for VEGFR2 and PDGFRb.
The IHC protein expression was evaluated and dis-
cussed by two observers blinded with temporary
number tags for response data.
Statistical analyses
Comparisons between categorical variables were per-
formed by Fisher’s exact test. In the analyses of the
IHC markers, we dichotomized the index score into
absent/low versus median/high protein expression and
tested the different groups against the frequency of
OR in the patients. Logistic regression analysis was
used to test the relative importance of predictive fac-
tors for sunitinib response. Sample size calculations
(alpha 0.05/power 80%) indicated that 20 patients per
group based on candidate marker expression were
needed to detect a difference between 10 and 50% of
patients having an OR to treatment with sunitinib.
Thus, 46 patients were enrolled. Kaplan–Meier esti-
mates were constructed for time-to-event endpoints
such as PFS and OS, and log rank-test was applied
for testing of differences between groups. Log-rank
was applied for testing of differences between groups
for PFS and OS. All P values are two-sided. Statisti-
cal investigations were performed using IBM SPSS
Statistics version 24.
Table 1. Baseline patients characteristics
Study cohort




















*International Metastatic Renal Cell Carcinoma Database Consortium.
**World Health Organisation.
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Thirty-eight of 41 (92.7%) cases had significant
tumour tissue for quantification of IL6Ra. IL6Ra was
expressed in the cytoplasm and membrane in 38/38
(100%) (median SI5 6) (Figure 1A, B).
Low expression of IL6Ra was significantly associ-
ated with OR (Fisher’s exact test, p5 0.03) (Table
2). Sixty-six percent of the patients with response
data available showed median/high expression of
IL6Ra in tumour cells, and only 10% of these
patients responded to treatment with sunitinib,
whereas 46% of patients with low expression
responded (Table 2) (Figure 2). Logistic regression
analysis was used to test the relative importance of
the candidate predictive factors [International Meta-
static Renal Cell Carcinoma Database Consortium
(IMDC) risk groups, baseline CRP, baseline Euro-
pean Organization for Research and Treatment of
Cancer Quality of Life (EORTC QoL) symptom scale
and IL6Ra] for OR to sunitinib. Of these, IL6Ra was
the only significant predictive factor of OR in the
Figure 1. Expression of tumour biomarkers by IHC. Representa-
tive microscopic images for IL6Ra (A,B), IL6 (C,D), JAG1 (E,F),
VEGF-A (G,H), VEGFR2 (I,J), PDGFRb (K,L), and HSP27 (M,N) in
tumour tissue. All pictures taken with x400 magnification; A, G,
and M represent low tumour expression of the marker applied;
C, E, G, I, K, and M represent absent/low tumour expression of
the marker applied; and B, D, F, H, J, L, and N represent
median/high tumour expression of the marker applied.
Table 2. IHC biomarkers in relation to response
Variable




n (%) P value††
IL6Ra 0.03
SI‡5 1–3 5(46) 6(54)
SI5 4–9 2(10) 19(90)
IL6 0.39
SI5 0–2 5(31) 11(69)
SI5 3–9 2(13) 13(87)
JAG1 1.00
SI5 0–2 4(22) 14(78)
SI5 3–9 3(23) 10(77)
VEGF-A 1.00
SI5 1–3 2(25) 6(75)
SI5 4–9 5(20) 20(80)
VEGFR2 0.66
SI5 0–2 3(27) 8(73)
SI5 3–9 4(18) 18(82)
PDGFRb 1.00
SI5 0–1 3(23) 10(77)
SI5 2–9 4(25) 12(75)
HSP27 0.38
SI5 1–3 4(33) 8(67)
SI5 4–9 3(15) 17(85)




‡Staining index. Statistically significant comparisons (p< 0.05) are shown in
bold.
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final model, with an odds ratio of 7.9 (p5 0.03).
There was no statistically significant association
between IL6Ra and PFS or OS (Table 3). Median/
high expression of IL6Ra was significantly associated
with median/high expression of HSP27 (Fisher’s
exact test, p5 0.01) (Table 4). IL6Ra was not signifi-
cantly associated with serum CRP (s-CRP) or lactate
dehydrogenase (s-LDH).
IL6
Thirty-eight of 41 (92.7%) cases had sufficient
tumour tissue for quantification of IL6. Cytoplasmic
IL6 was expressed in 36/38 (94.7%) (median SI5 2)
(Figure 1C, D). IL6 was not significantly associated
with OR (Table 2). Absent/low expression of IL6
was significantly associated with improved PFS
Figure 2. Treatment response in relation to expression of IL6Ra.
Histogram showing the difference between absent/low and
median/high expression of IL6Ra in tumour cells according to
response. Ten percent of patients with median/high expression
experienced an objective response to treatment with sunitinib
compared with 46% of patients with absent/low expression.
Table 3. Survival analyses according to biomarker expression
Variable
PFS* OS**
Median 95% CI† P value†† Median 95% CI P value
IL6Ra 0.21 0.22
SI‡5 1–3 17.0 12.5–21.4 41.3 0.0–93.0
SI5 4–9 8.7 5.8–11.6 13.7 11.0–16.5
IL6 0.04 0.20
SI5 0–2 17.0 8.7–25.2 18.0 0.0–51.9
SI5 3–9 8.7 6.8–10.6 11.6 8.8–14.4
JAG1 0.80 0.63
SI5 0–2 12.9 6.3–19.6 13.7 11.2–16.2
SI5 3–9 16.5 0.0–35.5 19.7 7.6–31.9
VEGF-A 0.19 0.27
SI5 1–3 5.3 – 48.2 9.9–86.5
SI5 4–9 12.9 6.4–19.5 13.2 8.7–17.7
VEGFR2 0.09 0.45
SI5 0–2 17.0 6.5–27.5 15.6 8.8–22.4
SI5 3–9 9.1 5.9–12.2 12.1 5.9–18.3
PDGFRb 0.72 0.29
SI5 0–1 10.8 3.7–17.9 13.7 11.0–16.5
SI5 2–9 14.7 2.8–26.6 25.2 3.0–47.4
HSP27 0.86 0.62
SI5 1–3 9.1 1.6–16.5 25.2 0.0–53.3





‡Staining index. Statistically significant comparisons (p< 0.05) are shown in
bold.
Table 4. Analyses of patient characteristics and IHC biomarkers











< median 7(35) 13(65)














SI5 0–2 9(75) 3(25)
SI5 3–9 11(44) 14(56)
JAG1 0.08
SI5 0–2 10(77) 3(23)
SI5 3–9 10(44) 13(56)
VEGF-A 0.18
SI5 1–3 4(33) 8(67)
SI5 4–9 3(12) 22(88)
VEGFR2 1.00
SI5 0–2 5(42) 7(58)
SI5 3–9 9(36) 16(64)
PDGFRb 0.30
SI5 0–1 3(27) 8(73)
SI5 2–9 11(48) 12(52)
HSP27 0.01
SI5 1–3 8(67) 4(33)
SI5 4–9 5(20) 20(80)
*Staining index.
**Fisher’s exact test.
†International Metastatic Renal Cell Carcinoma Database Consortium.
††World Health Organisation. Statistically significant comparisons (p< 0.05)
are shown in bold.
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(median 17.0 versus 8.7 months, log rank p5 0.04)
(Table 3). There was a significant association
between absent/low expression of IL6 and absent/low
expression of JAG1 (Fisher’s exact test, p5 0.04),
low expression of VEGF-A (Fisher’s exact test,
p5 0.02), and absent/low expression of VEGFR-2
(Fisher’s exact test, p5 0.05) (Table 5). No statisti-
cally significant correlation was present between IL6
and IL6Ra (Table 4), s-CRP, or S-LDH.
JAG1
Thirty-eight of 41 (92.7%) cases had significant
tumour tissue for quantification of JAG1. JAG1 was
expressed in the cytoplasm and membrane in 28/38
(73.7%) (median SI5 2) (Figure 1E, F). There was
no significant association between JAG1 expression
and OR, PFS, or OS (Table 2 and 3). Absent/low
expression of JAG1 was significantly associated with
low expression of VEGF-A (Fisher’s exact test,
p5 0.01), whereas median/high expression of JAG1
tended to be associated with median/high expression
of IL6Ra (Fisher’s exact test, p5 0.08) (Table 5).
VEGF-A
Thirty-nine of 41 (95.1%) cases had significant
tumour tissue for quantification of VEGF-A. VEGF-
A was expressed in the cytoplasm of tumour cells in
all patients (median SI5 6) (Figure 1G, H). The
expression of VEGF-A was not significantly associ-
ated with OR, PFS, or OS (Tables 2 and 3).
VEGFR2
Thirty-nine of 41 (95.1%) cases had significant tumour
tissue for quantification of VEGFR2. VEGFR2 was
expressed in the cytoplasm and membrane in 31/39
(79.5%) (median SI5 3) (Figure 1I, J). No significant
association between VEGFR2 expression and OR was
present (Table 2). Cytoplasmic VEGFR2 expression
was not significantly associated with OS or PFS
(Table 3).
PDGFRb
Thirty-four of 41 (82.9%) cases had significant
tumour tissue for quantification of PDGFRb.
PDGFRb was expressed in the cytoplasm and mem-
brane in 21/34 (61.8%) (median SI5 2) (Figure 1K,
L). PDGFRb expression was not significantly associ-
ated with OR, PFS or OS (Tables 2 and 3).
Hsp27
Thirty-nine of 41 (95.1%) cases had significant
tumour tissue for quantification of HSP27. HSP27
was expressed in the cytoplasm of tumour cells in all
patients (median SI5 6) (Figure 1M, N). HSP27
expression was not significantly associated with OR,
OS, or PFS (Tables 2 and 3).
Discussion
Ever since rTKI was introduced as first line treatment
for mRCC, an intensive search for predictive markers
has been performed to optimize treatment. In a recent
paper, we found evidence for a predictive role for
CRP in sunitinib treatment of RCC suggesting a
potential role for markers of anti-tumour immune
responses [4]. Lymphocytic infiltration in RCC has
Table 5. Analyses of patient characteristics and IHC biomarkers











< median 8(40) 12(60)














SI5 1–3 9(75) 3(25)
SI5 4–9 11(44) 14(56)
JAG1 0.04
SI5 0–2 14(74) 5(26)
SI5 3–9 6(35) 11(65)
VEGF-A 0.02
SI5 1–3 8(89) 1(11)
SI5 4–9 11(39) 17(61)
VEGFR2 0.05
SI5 0–2 11(73) 4(27)
SI5 3–9 8(36) 14(64)
PDGFRb 0.17
SI5 0–1 10(71) 4(29)
SI5 2–9 9(45) 11(55)
HSP27 0.18
SI5 1–3 9(69) 4(31)
SI5 4–9 11(44) 14(56)
*Staining index.
**Fisher’s exact test.
†International Metastatic Renal Cell Carcinoma Database Consortium.
††World Health Organisation. Statistically significant comparisons (p< 0.05)
are shown in bold.
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been shown to be associated with poor survival [37]
and IL6 might be used as a surrogate marker of host
immunity in patients with RCC [38]. Tissue and
serum levels of IL6 are elevated in RCC, and high
levels of IL6 have been associated with elevated
CRP in RCC patients [18,19]. Dysregulation of the
cytokine IL6 and its receptor is involved in the
pathogenesis of several diseases, such as autoimmune
conditions and cancer [39]. In classic signalling, IL6
binds to the complex of IL6Ra and gp130 to induce
intra-cellular signals [29,40]. Almost all cells in the
body express gp130 [28], but only some have the
IL6Ra subunit to bind IL6 [39].
Here, we investigated the expression of IL6Ra in
RCC tumour cells and found that expression of IL6Ra
may predict response to rTKI treatment. In our study,
IL6Ra was expressed in all cases, and low expression
of IL6Ra was significantly associated with OR to
sunitinib treatment. Only 10% of patients showing
increased expression of IL6Ra responded, suggesting
that high IL6Ra expression might represent an impor-
tant mechanism of resistance to anti VEGF therapy in
ccRCC. The strong association between IL6Ra expres-
sion and treatment response, as well as the lack of a
significant association with PFS and OS, suggest that
IL6Ra expression adds more predictive than prognos-
tic information in patients with mccRCC treated with
sunitinib. Costes et al found a significant association
between IL6R expression and OS in patients with pri-
mary RCC tumours. In their study, all patients under-
went nephrectomy and six out of 38 patients had
metastatic disease [30]. Eighteen percent of the 38
patients and 83% of the 6 patients with synchronous
metastatic disease showed positive expression of
IL6Ra. In our cohort of patients with primary inoper-
able or metastatic disease, 100% of the patients
showed positive IL6Ra expression.
Regarding the IL6 ligand, absent or low expression
was associated with disease outcome in the survival
analyses of PFS. The group with low expression of
IL6 had almost a doubling of PFS compared to
median/high expression. In line with previous reports
[18,19], this suggests that IL6 expression has prog-
nostic value independent of the treatment given.
Elevated serum IL6 has been associated with poor
survival in RCC [19,30,41]. Tumour cells produce
IL6 in response to cellular stress such as hypoxia,
and enhanced levels of IL6 are associated with
increased tumour cell invasion [23,24]. Kwon et al
found elevated IL6 to have a stimulating effect on
endothelial cells, and this may be a reason for resist-
ance to anti-VEGF therapy [42]. As a response to
cellular stress, IL6 activation of the transcription fac-
tor STAT3 drives angiogenesis by inducing
expression of VEGF and fibroblast growth factor by
tumour cells, and thereby supports vascularization
required for tumour growth and metastasis [43,44].
Fu et al found that IL6 and IL6Ra co-expression
might be an independent early-stage immunological
prognostic factor for patients with organ-confined
ccRCC [45]. Tran et al showed a significant increase
in PFS in patients treated with another rTKI (pazopa-
nib) versus placebo, when analysing patients with
high serum IL6 [46]. Our results are in support of
previous reports indicating that high levels of
inflammation-associated cytokines are detrimental for
the outcome of sunitinib treatment [21].
When correlating IL6Ra to the other biomarkers
under investigation, we found that median/high
expression of IL6Ra was significantly associated
with median/high expression of HSP27. Both IL6
and HSP27 signalling constitute cellular stress
responses and increase the level of VEGF through
activation of STAT3 [44,47]. Schuster et al found
that high HSP27 expression in melanoma metastases
predicts response to anti-VEGF treatment [48]. In the
present study, we did not find an association between
HSP27 expression and treatment response. Blay et al
previously showed that a higher IL6 level correlated
with increased concentration of CRP [49]. In our
study, IL6 was not significantly associated with CRP.
JAG1 is one of five Notch ligands. The Notch sig-
nalling pathway is a regulator of tumour angiogene-
sis, stem cell self-renewal, cell fate determination,
epithelial cell polarity/adhesion, cell division, and
apoptosis [31–34]. In mccRCC, high JAG1 was asso-
ciated with poor prognosis [50]. In aggressive breast
cancer cells, Sansone et al found that IL6 could stim-
ulate Notch-3-dependent upregulation of JAG1 in an
autocrine matter in response to hypoxic conditions
[35]. In our present cohort, the expression of JAG1
was not related to OR, but absent/low expression of
IL6 was significantly associated to absent/low expres-
sion of JAG1. These JAG1 results may support a
possible interaction of JAG1, Notch, and IL6 [35].
Moreover, absent/low expression of IL6 was shown
to be significantly associated with low expression of
VEGF-A and absent/low expression of VEGFR2, fur-
ther supporting an important role of IL6 signalling
the regulation of angiogenesis in mRCC.
Along with a stimulating effect on tumour-
associated angiogenesis, VEGF-A also plays an
important role in the local immune response during
wound healing as well as in tumours by inducing
accumulation of immature dendritic cells, myeloid-
derived suppressor cells, regulatory T cells, and
inhibiting the migration of T lymphocytes to the
tumour [16]. Whereas VEGF-A was expressed in all
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tumours, we found no association between the level
of expression and response, in line with other studies
[5,6]. VEGF-A signals through VEGFR2 on endothe-
lial cells to activate angiogenesis [51]. Dornbush
et al found an association between high expression of
VEGFR2 and good treatment response [6], and Tera-
kawa et al also found high expression of VEGFR2 to
be beneficial to sunitinib treatment [52]. In the last
paper, the majority of patients were in the good prog-
nostic group whereas in ours, the majority were in
the poor prognostic group [4].
PDGF receptors are key regulators of mesenchymal
cells of the tumour microenvironment in several
malignancies [53]. In cancers, an association between
high stromal PDGFRb expression or signalling and
poor prognosis is reported [53]. Still, we did not find
an association with response in our present data.
In addition to the lack of a control group, our study
has some weaknesses. First, the number of patients
included is low and thereby the study lacks the statisti-
cal power to detect minor differences in response rates
between groups based on the biomarkers under inves-
tigation. Thus, our findings should be validated in an
independent and larger cohort of patients.
Second, the reproducibility of the quantification of
protein expression used in this study also needs to be
validated in a separate patient cohort. Still, our data
suggest that both angiogenesis and tumour immune
responses play important roles in anti-VEGF therapy.
Whereas expression levels of the IL6 ligand in
tumour cells provided significant prognostic informa-
tion, reduced expression of its receptor IL6Ra was sig-
nificantly associated with response to sunitinib, thereby
suggesting that upregulation of IL6Ra might represent
an important mechanism of resistance. Expression of
IL6Ra might be a potential predictive biomarker to
guide treatment of patients with mccRCC.
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A B S T R A C T
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and
anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). Response rates and
duration of response show considerable variation, and adverse events have major influence on patient's quality
of life. The need for predictive biomarkers to select those patients most likely to respond to receptor tyrosine
kinase inhibitors (rTKI) upfront is urgent. We investigated the predictive value of plasma interleukin-6 (pIL6),
interleukin-6 receptor α (pIL6Rα) and interleukin 6 signal transducer (pIL6ST) in mccRCC patients treated with
sunitinib.
Material and methods: Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib were
included. Full blood samples were collected at baseline before start of sunitinib and after every second cycle of
treatment during the study time. pIL6, pIL6R and pIL6ST at baseline and week 12 samples were analysed by
ELISA. The predictive potential of the candidate markers was assessed by correlation with response rates
(RECIST). In addition, progression free survival (PFS) and overall survival (OS) were analysed.
Results: Low pIL6 at baseline was significantly associated with improved response to sunitinib (Fisher's exact
test, p < 0.01). Furthermore, low pIL6 at baseline was significantly associated with improved PFS (log rank,
p=0.04). In addition, patients with a decrease in concentration of pIL6R between baseline and week 12 showed
significantly improved PFS (log rank, p=0.04) and patients with high pIL6ST at baseline showed significantly
improved OS (log rank, p=0.03).
Conclusion: Low pIL6 at baseline in mccRCC patients treated with sunitinib predicts improved treatment re-
sponse, and might represent a candidate predictive marker.
Introduction
Renal cell carcinoma (RCC) is the 7th most common cancer type
among men and 10th most common among women worldwide [1].
70–85% of RCC are clear cell RCC (ccRCC). After anti-angiogenic re-
ceptor tyrosine kinase inhibitors (rTKIs) showed superior efficacy over
interferon and interleukin-2 therapy, currently rTKIs are first line
treatment option for ccRCC [2]. Due to the diversity of treatment re-
sponse and toxicity among patients, the research community in-
vestigates potential predictive markers of response to antiangiogenic
treatment.
Vascular endothelial growth factor (VEGF) is the most important
mediator of tumour-associated angiogenesis in renal cell carcinoma [2].
In addition, some reports suggest a role of systemic inflammation in
development and progression of RCC [3–5]. Along with a stimulating
effect on tumour associated angiogenesis, VEGF also plays an important
role in the local immune response during wound healing as well as in
tumours by inducing accumulation of immature dendritic cells, mye-
loid-derived suppressor cells, regulatory T cells, and VEGF inhibits the
migration of T lymphocytes to the tumour [6].
Inflammation is one of the hallmarks of cancer, involved in devel-
opment and maintenance of cancer [7]. In a recent study, we found a
significant correlation between low serum C-reactive protein (CRP) and
objective response (OR) in mccRCC patients treated with sunitinib [8].
CRP is regarded a relevant biomarker for systemic inflammation [9].
Interleukin-6 (IL6) has a role in inflammation, infection responses and
the regulation of metabolic, regenerative and neural processes [10–13].
Tissue and serum levels of IL6 are elevated in RCC and secreted when
https://doi.org/10.1016/j.ctarc.2019.100127
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T
cells are exposed to hypoxia. Enhanced level of IL6 results in RCC cell
invasion [10,14]. IL6 is also shown to be closely related to hypoxia-
inducible factor 1- α (HIF-1α) as well as increased VEGF activity [15].
The prognostic information of IL6 and IL6-receptor (IL6R) is well
known [10,16]. A predictive value of IL6 levels has also been reported
for response to immune checkpoint inhibitors [17]. IL6 signals in cells
via classic (membrane-bound) and trans-signalling (soluble) pathways
[18,19]. The interleukin 6 receptor α (IL6Rα) binds to the interleukin 6
signal transducer (IL6ST), also known as glycoprotein 130 (gp130)
protein receptor to transduce the signal. In a recent study, we identified
ccRCC tumour cell expression of IL6Rα as a predictive marker of re-
sponse to sunitinib treatment [20]. The membrane-bound IL6Rα is
found on hepatocytes and different leukocytes [21]. In trans-signalling,
soluble IL6 binds to soluble IL6R and the complex binds to cells ex-
pressing IL6ST [22]. Soluble IL6ST is also detected in the blood and has
been shown as an inhibitor of IL6 trans-signalling [23].
In the present work, we investigated the predictive and prognostic




Between 2007 and 2015, forty-six patients with radiologically
confirmed progressive mccRCC were enrolled in an open-label, single-
arm phase II study at Haukeland University Hospital, Norway.
Treatment was given as sunitinib 50mg/day on schedule four weeks
on/ two weeks off until disease progression, significant toxicity or
consent withdrawal. The study has previously been reported elsewhere
[8,24]. In summary, we observed 1 complete response (CR), 7 partial
responses (PR) and 18 patients with stable disease (SD) ≥ 6 months.
Twelve patients showed progressive disease (PD). Eight patients
stopped treatment before week 12 and were recorded as non-evaluable
for response rates and PFS. In response analyses objective response
(OR) is CR and PR together versus SD and PD and clinical benefit (CB) is
CR, PR and SD together versus PD. Clinical information is provided in
Table 1.
Ethics
The study was conducted in accordance with the ethical principles
of the Declaration of Helsinki and the International Conference on
Harmonization of Good Clinical Practice. The protocol was approved by
the Regional Ethics Committee (REK number 080/07 and REK number
78/05) and the Norwegian Medicines Agency. All participating patients
provided signed informed consent before enrolment.
Blood samples
Full blood samples were collected at baseline before start of suni-
tinib and after every second cycle of treatment during the study time.
After centrifugation, Na-heparin plasma samples were stored frozen at
−80 °C. For ELISA we used the heparin plasma sample tubes, which
was de-frozen in room temperature, shaken and then centrifuged for
different amount of fibrin precipitation.
Enzyme-linked immunosorbent assay (ELISA)
The antibodies used were human IL6 (P05231), human IL6R
(BMS214) and human IL6ST (EHIL6ST). Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA provided all three. For IL6 we used a
ready-to-use self-coating system kit (Invitrogen) and an ELISA 96-well
flat-bottom plate (Nune MaxiSorp flat-bottom (catalog number
44–2404), Invitrogen). For IL6R we used a ready-to-use sandwich ELISA
96 micro well plate coated kit with human IL6R (Invitrogen). For IL6ST
we used a ready-to-use self-coating system kit (Invitrogen). Phosphate
buffered saline (PBS); containing 0.05% (v/v) Tween 20 (PBS-T)
(Prod.nr. 822,184, Merck, USA) was used as washing buffer. All other
buffers used were from the respective ELISA kit. The staining process
was performed according to the manufactures manual and was analysed
at 450 nm with a microplate reader (Molecular Devices Emax).
Evaluation of ELISA results
We evaluated the ELISA results in according to the manufactures
manual. SoftMax Pro was used to evaluate the ELISA data and then
transferred to SPSS for statistical analysis. We categorized the baseline
ELISA variables (pIL6, pIL6R, pIL6ST), into low (below median) versus
high (above median). The change in pIL6, pIL6R and pIL6ST con-
centration between baseline and week 12 were divided into three ca-
tegories (decrease, stable, increase). We tested the decrease group
versus the stable and increase groups. The variables referred in the
paper are baseline values if not otherwise specified.
Tumour tissue samples and data
Immunohistochemically tumour tissue expression of interleukin-6
receptor α (IL6Rα), interleukin-6 (IL6), jagged1 (JAG1), vascular en-
dothelial growth factor A (VEGF-A), vascular endothelial growth factor
2 (VEGFR2), platelet-derived growth factor receptor β (PDGFRβ) and
heat shock protein 27 (HSP27) are previously published [24].
Statistical analyses
Comparisons between categorical variables were performed by
using the Fisher's exact test and Pearson chi-square. The Mann–Whitney
U test was used to compare the distribution of continuous variables
between two groups such as responders and non-responders. Logistic
regression analysis was used to test the relative importance of pre-
dictive factors for sunitinib response. Sample size calculations (alpha
0.05/ power 80%) indicated that 20 patients per group based on can-
didate marker expression were needed to detect a difference between
10% and 50% of patients having a response to treatment with sunitinib.
Kaplan–Meier estimates were constructed for time-to-event endpoints
such as PFS and OS, and log rank-test was applied for testing of dif-
ferences between groups. All p-values are two-sided. Statistical in-
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Forty-five of 46 (98%) cases had heparin plasma available for
quantification of pIL6 at baseline. Median value was 6.90 pg/ml (range
0.9–36.5 pg/ml). Twenty-six of 46 (56%) cases had heparin plasma
available for quantification of pIL6 at week 12. Median value was
8.90 pg/ml (range 1.0–18.8 pg/ml). Low baseline pIL6 was significantly
associated with clinical benefit (CB) (Fisher's exact test, p = <0.01)
(Table 2). Similarly, the continuous values of pIL6 was significantly
associated with CB (Mann–Whitney U test, p = <0.01) (Table 2). Lo-
gistic regression analysis was used to test the relative importance of the
following candidate predictive factors for clinical benefit to sunitinib;
International Metastatic Renal Cell Carcinoma Database Consortium
(IMDC) risk groups, baseline CRP, baseline European Organization for
Research and Treatment of Cancer Quality of Life (EORTC QoL)
symptom scale and pIL6. Of these, pIL6 was the only significant pre-
dictive factor for CB in the final model, with an odds ratio of 23.4
(p=<0.01). Low pIL6 was significantly associated with improved PFS
(median 14.7 months vs 5.3 months, log rank, p=0.04) (Table 3). Low
pIL6 was not significantly associated with OS (Tables 2 and 3).
Low pIL6 was significantly associated with normal CRP (Pearson
chi-square, p=0.05), but not with tumour tissue expression of IL6 or
IL6Rα (Supplementary Table 1).
pIL6R
Forty-six of 46 (100.0%) cases had significant heparin plasma for
quantification of pIL6R at baseline. Median value was 190.40 ng/ml
(range 115.0–288.9 ng/ml). Twenty-eight of 46 (60.9%) cases had
significant heparin plasma for quantification of pIL6R at week 12.
Median value was 164.13 ng/ml (range 94.7–248.4 ng/ml). pIL6R was
not significantly associated with CB (Table 2). Low pIL6R tended to be
associated with improved OS (median 26.3 months vs 13.7 months, log
rank, p=0.06) and not with PFS (Table 3).
Low pIL6R at baseline was significantly associated with age under
median (Pearson chi-square, p=0.04)). pIL6R was not significantly
associated with s-CRP or tumour tissue expression of IL6 or IL6Rα
(Supplementary Table 2).
pIL6ST
Forty-five of 46 (98.0%) cases had significant heparin plasma for
quantification of pIL6ST at baseline. Median value was 170.94 ng/ml
(range 102.2–260.84 ng/ml). Twenty-nine of 46 (63.0%) cases had
significant heparin plasma for quantification of pIL6ST at week 12.
Median value was 161.84 ng/ml (range 120.58–291.84 ng/ml). pIL6ST
was not significantly associated with CB (Table 2). High pIL6ST was
significantly associated with improved OS (median 25.2 months vs 12.7
months, log rank, p=0.04) and tended to be associated with improved
PFS (median 12.9 months vs 8.4 months, log rank, p=0.06) (Table 3).
pIL6ST was not significantly associated with s-CRP or tumour tissue
expression of IL6 or IL6Rα (Supplementary Table 3).
Change in candidate biomarkers between baseline and week 12
Twenty-five of 46 (54.3%) cases had significant heparin plasma for
quantification of pIL6 from baseline and week 12. Median value of the
change in pIL6 between baseline and week 12 was 1.99 pg/ml (range:
−13.4 to +11.9 pg/ml). The change in pIL6 was not significantly as-
sociated with PFS or OS (Table 3).
Twenty-eight of 46 (60.9%) cases had significant heparin plasma for
quantification of change in pIL6R between baseline and week 12.
Median value of the change in pIL6R between baseline and week 12 was
−24.63 ng/ml (range −63.8 to 17.5 ng/ml). The cases with decrease
had significantly better PFS than cases with stable or increased change
of pIL6R between baseline and week 12 (median missing vs 8.7 months,
log rank, p=0.04). We found no association with OS (Table 3).
Twenty-nine of 46 (63.0%) cases had significant heparin plasma for
quantification of change in pIL6ST between baseline and week 12.
Median value of the change in pIL6ST between baseline and week 12
was −2.40 ng/ml (range −108.68 to 137.87 ng/ml). We found no as-
sociation with PFS or OS (Table 3).
Discussion
Recently, an inverse response relationship was reported for VEGF
inhibitor (VEGFi) treatment and immune checkpoint inhibitor treat-
ment according to IMDC risk groups [25], and new predictive bio-
markers are needed to further optimize treatment for individual pa-
tients. The ongoing search for biomarkers to optimize VEGFi treatment
in renal cell carcinomas has so far been unsuccessful in finding pre-
dictive biomarkers useful for clinical practice. In a previous paper, we
presented results suggesting a predictive role of CRP [8]. This might
indicate that the immunomodulating effect of anti VEGF therapy plays
an important role in treatment response in addition to the effect on
angiogenesis. In the follow-up investigation, we found that low tumour
cell expression of IL6Rα was significantly associated with improved
objective response to sunitinib and low tumour cell expression of IL6
was significantly associated with PFS and OS [24]. In our present work,
we investigated the plasma level of baseline IL6, IL6R and IL6ST in the
Table 2
Plasma biomarkers in relation to response.
Variable Best overall tumor response (RECIST ver. 1.1)























Change in pIL6ST between





CB PD p valueg
pIL6 baseline <0.01
Mean value 6.13 14.82
pIL6R baseline 0.59
Mean value 189.30 183.47
pIL6ST baseline 0.21
Mean value 179.43 158.63
a Clinical benefit (Complete+Partial response+ Stable disease).
b Progressive disease.
c Fisher's exact test.
d Plasma Interleukin 6.
e Plasma Interleukin 6 receptor.
f Plasma Interleukin 6 signal transducer.
g Mann-Withney U test.
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same cohort with established metastatic ccRCC. Low baseline level of
pIL6 was significantly associated with clinical benefit of sunitinib
treatment and improved PFS.
Tissue and serum levels of IL6 are elevated in RCC, and high levels
of IL6 have been associated with elevated CRP in RCC patients [26,27].
IL6 signals cells via membrane-bound (classic) and soluble (trans-sig-
nalling) pathways [18,19]. The trans-signalling pathway is considered
to be pro-inflammatory [28]. Elevated IL6 has been associated with
poor survival in renal cell carcinoma and resistance to TKI treatment
[29–32]. Tumour cells produce IL6 in response to cellular stress such as
hypoxia, and enhanced levels of IL6 is associated with increased tumour
cell invasion [10,14]. Kwon et al. found a stimulating effect of elevated
IL6 on endothelial cells, which might represent a resistance mechanism
to anti-VEGF therapy [33]. As a response to cellular stress, IL6 activa-
tion of the transcription factor STAT3 drives angiogenesis by inducing
expression of VEGF and fibroblast growth factor (bFGF) by tumour
cells, and thereby supports vascularization required for tumour growth
and metastasis [34,35]. Our results are in support of previous reports
indicating that high levels of inflammation-associated cytokines are
negative for the outcome of treatment [13]. Elevated levels of IL6
among patients with poor response was also found in a recent work of
Mizuno, investigating angiogenic, inflammatory and immunologic
markers of sunitinib treatment in 56 patients with metastatic RCC [31].
However, they did not include patients with poor IMDC prognostic
score. Our findings may therefore show that we can include this group
as well. Tran et al. found opposite results, where a significantly increase
in PFS in patients treated with another rTKI (pazopanib) versus pla-
cebo, in patients with high serum IL6 [36].
The baseline value of soluble IL6R in plasma was not significantly
associated with response variables in this study, though low pIL6R
tended to be associated with improved OS. In our previous paper, low
tumour cell expression of IL6Rα was beneficial for treatment response.
The prognostic value of IL6R expression have previously been pre-
sented, where Costes et al. found a significant association between IL6R
expression and OS in patients with primary RCC tumours [16]. The
complexity of membranous and soluble IL6R is well discussed in several
reviews [10,34,37].
Membranous IL6ST is ubiquitous expressed in human tissue [38].
IL6ST and IL6R form a buffer for pIL6 in the blood, and is purposed to
be a mechanism by which the organism protects itself from unspecific
overstimulation by IL6ST [37]. Soluble IL6ST is an inhibitor of IL6.
Even though the range of pIL6ST in our cohort was lower than a normal
cohort, the group with under median level of pIL6ST level had worse OS
(Table 3), in line with previous findings [29]. This may support the idea
of a well-functioning buffer to protect against unspecific over-
stimulation by IL6-trans-signaling [37].
The cases with sunitinib induced reduction of pIL6R after two
rounds of treatment had improved PFS. A reduction of pIL6R might be
supported by the theory that trans-signaling pathways mediates cancer
development [28,39]. Our results suggest that this might be used as a
marker of beneficial on-treatment response, and suggest a relation be-
tween IL6Rα in tumour cells and level of circulating pIL6R.
In addition to the lack of a control group, our study has some
weaknesses. First, the number of patients included is low and thereby
the study lacks the statistical power to detect minor differences in re-
sponse rates between groups based on the biomarkers under in-
vestigation. Thus, our findings should be validated in an independent
and larger cohort of patients. Still, our data strongly suggest that bio-
markers associated with tumour immune responses might be important
in patients treated with anti-VEGF therapy.
Conclusion
Low level of plasma IL6 provides significant predictive information
about response to sunitinib, and our data thereby suggest that up-reg-
ulation of IL6 might represent an important mechanism of resistance.
Baseline measurement of this biomarker might guide clinical decision
making in treatment of patients with mccRCC.
Clinical practice points
The anti-angiogenic receptor tyrosine kinase inhibitor sunitinib is
first line treatment in metastatic renal cell carcinoma. Today there are
no established predictive markers in clinical use. Inflammation is an
Table 3
Survival analyses according to pIL6, pIL6R and pIL6ST.
Variable PFSa OSb
Median 95% CIc p-valued Median 95% CI p-value
pIL6e baseline 0.04 0.11
Low 14.7 1.9–27.6 25.2 15.6–34.8
High 5.3 1.8–8.8 8.3 3.0–13.6
pIL6Rf baseline 0.12 0.06
Low 14.7 1.6–27.8 26.3 4.7–47.9
High 8.7 7.6–9.8 13.7 11.0–16.5
pIL6STg baseline 0.06 0.04
Low 8.4 3.0–13.8 12.7 8.3–17.2
High 12.9 5.9–20.0 25.2 15.7–34.7
Change in pIL6 between baseline and week 12 0.03 0.63
Decrease 8.4 0.5–16.2 25.2 9.5–40.9
Stable/Increase 17.0 9.0–25.0 19.7 03–39.2
Change in pIL6R between baseline and week 12 0.04 0.40
Decrease −h −h 26.0 24.3–27.6
Stable/Increase 8.7 7.4–9.9 17.5 7.2–27.7
Change in pIL6ST between baseline and week 12 0.30 0.95
Decrease 16.5 1.9–32.2 19.7 9.0–30.5
Stable/Increase 8.4 6.0–10.7 13.9 9.3–18.5
a Progression free survival.
b Overall survival.
c Confidence interval.
d Log rank test.
e Plasma interleukin 6.
f Plasma interleukin 6 receptor.
g Plasma interleukin 6 signal transducer.
h Median survival cannot be calculated, due to less than 50% censored.
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important part of cancer. In our study, we find that low level of inter-
leukin 6 in plasma may predict treatment response of sunitinib and
guide clinicians in making better treatment plans in renal cell carci-
noma. The results suggest that up-regulation of plasma IL6 might re-
present an important mechanism of resistance. If validated in in-
dependent patient cohorts, the biomarker can easily be implicated into
routine practice for a low cost using ELISA.
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MicroAbstract
Anti-angiogenic treatment is first line treatment in metastatic renal
cell carcinoma. There are presently no clinically useful predictive
markers. In this study, we evaluate markers of tumor immune responses
and angiogenesis. We find that low level of plasma interleukin-6 may
predict response to sunitinib treatment. These results might represent
an important mechanism of resistance.
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Supplementary table 1 Biomarkers in relation to plasma interleukin 6 
Variable Plasma interleukin 6 






Plasma markers    
Baseline pIL6R2   0.77 
  Low  11(48) 12(52)  
  High 12(55) 10(45)  
Baseline pIL6ST3   0.55 
  Low  10(46) 12(54)  
  High 13(59) 9(41)  
Change in pIL6R between baseline and week 
12 
  0.41 
  Decrease 6(67) 3(33)  
  Stable/Increase 7(41) 10(59)  
Change in pIL6ST between baseline and 
week 12 
  0.41 
  Decrease 5(71) 2(29)  
  Stable/Increase 11(50) 11(50)  
Clinicopathologic markers at baseline:    
Sex   0.37 
  Female 7(41) 10(59)  
  Male 16(57) 12(43)  
Age   0.77 
  ≤ median  11(48) 12(52)  
  > median 12(55) 10(45)  
IMDC4 criteria   0.175 
  Favourable 4(80) 1(20)  
  Intermediate  9(69) 4(31)  
  Poor 8(42) 11(58)  
WHO6 performance status - No. (%)   0.54 
  0 16(55) 13(45)  
  1 7(44) 9(56)  
Hypertension baseline    0.14 
  Yes  15(63) 9(37)  
  No 8(38) 13(62)  
s-CRP7    0.07 
  ≤ 10  12(71) 5(29)  
  > 10 11(41) 16(59)  
NLR8 ratio > 3 vs ≤ 3   0.53 
  ≤ 3  11(46) 13(54)  
  > 3 10(59) 7(41)  
Number of disease sites - No. (%)   0.575 
  1 4(40) 6(60)  
  2 5(46) 6(55)  
  ≥3 14(58) 10(42)  
Quality of life at baseline    
Function scale   0.73 
  Lower 3 quartiles 5(46) 6(54)  
  Upper quartile 18(55) 15(45)  
Symptom scale   0.30 
  Lower 3 quartiles 19(58) 14(42)  
  Upper quartile  4(36) 7(64)  
Immunohistochemistry -tumor expression of    
Interleukin 6    1.00 
2 
 
  SI89 = 0-2  10(50) 10(50)  
  SI = 3-9 9(53) 8(47)  
Interleukin 6 receptor α    1.00 
  SI = 1-3  6(46) 7(54)  
  SI = 4-9 12(50) 12(50)  
Jagged 1   0.74  
  SI = 0-2  10(48) 11(52)  
  SI = 3-9 9(56) 7(44)  
VEGFA10    1.00 
  SI = 1-3  3(43) 4(57)  
  SI = 4-9 15(48) 16(52)  
VEGFR211   1.00 
  SI = 0-2  7(50) 7(50)  
  SI = 3-9 11(46) 13(54)  
PDGFRβ12   0.49 
  SI = 0-1  6(43) 8(57)  
  SI = 2-9 11(58) 8(42)  
HSP2713   1.00 
  SI = 1-3  7(54) 6(46)  
  SI = 4-9 12(48) 13(52)  
 
1Fisher’s exact test. 2Plasma Interleukin 6 receptor 3Plasma Interleukin 6 signal transducer 4The 
International Metastatic Renal Cell Carcinoma Database Consortium. 5Pearson Chi-Square 6World 
Health Organization 7C-reactive protein. 8Neutrophil/lymphocyte ratio. 9Staining index. 10Vascular 
endothelial growth factor A. 11Vascular endothelial growth factor receptor 2. 12Platelet derived 




Supplementary table 2 Biomarkers in relation to plasma interleukin 6 receptor 
 Plasma interleukin 6 receptor 
 ≤ median 
n(%) 




    
ELISA markers:    
Baseline pIL62   0.77 
  Low 11(48) 12(52)  
  High 12(55) 10(45)  
Baseline pIL6ST3   0.08 
  Low 8(35) 15(65)  
  High 14(64) 8(36)  
Change in pIL6 between baseline and week 
12 
  0.66 
  Decrease 3(43) 4(57)  
  Stable/Increase 10(59) 7(41)  
Change in pIL6ST between baseline and 
week 12 
  0.39 
  Decrease 5(71) 2(29)  
  Stable/Increase 10(46) 12(54)  
Clinicopathologic markers at baseline:    
Sex   1.00 
  Female 9(53) 8(47)  
  Male 14(48) 15(52)  
Age   0.08 
  ≤ median  15(65) 8(35)  
  > median 8(35) 15(65)  
IMDC4 criteria   0.715 
  Favorable 4(67) 2(33)  
  Intermediate  7(54) 6(46)  
  Poor 9(47) 10(53)  
WHO6 performance status - No. (%)   0.76 
  0 16(53) 14(47)  
  1 7(44) 9(56)  
Hypertension   0.04 
  Yes  16(67) 8(33)  
  No 7(32) 15(68)  
s-CRP7   0.76 
  ≤ 10  8(44) 10(56)  
  > 10 14(52) 13(48)  
NLR8 ratio > 3 vs ≤ 3   1.00 
  > 3  9(53) 8(47)  
  ≤ 3 12(48) 13(52)  
Number of disease sites - No. (%)   0.335 
  1 6(60) 4(40)  
  2 7(64) 4(36)  
  ≥3 10(40) 15(60)  
Quality of life at baseline:    
Function scale   0.09 
  Lower 3 quartiles 3(27) 8(73)  
  Upper quartile 20(59) 14(41)  
Symptom scale   0.31 
  Lower 3 quartiles 19(56) 15(44)  
  Upper quartile  4(36) 7(64)  
Immunohistochemistry -tumor expression 
of: 
   
Interleukin 6    0.75 
4 
 
  SI9 = 0-2  12(60) 8(40)  
  SI = 3-9 9(50) 9(50)  
Interleukin 6 receptor α    1.00 
  SI = 1-3  7(54) 6(46)  
  SI = 4-9 13(52) 12(48)  
Jagged 1   0.75 
  SI = 0-2  12(57) 9(43)  
  SI = 3-9 8(47) 9(53)  
VEGFA10    0.42 
  SI = 1-3  5(71) 2(29)  
  SI = 4-9 16(50) 16(50)  
VEGFR211   1.00 
  SI = 0-2  8(53) 7(57)  
  SI = 3-9 13(54) 11(46)  
PDGFRβ12   0.73 
  SI = 0-1  7(50) 7(50)  
  SI = 2-9 12(60) 8(40)  
HSP2713   0.74 
  SI = 1-3  8(62) 5(38)  
  SI = 4-9 13(50) 13(50)  
 
1Fisher’s exact test. 2Plasma Interleukin 6. 3Plasma Interleukin 6 signal transducer 4The International 
Metastatic Renal Cell Carcinoma Database Consortium. 5Pearson Chi-square 6World Health 
Organization 7C-reactive protein. 8Neutrophil/lymphocyte ratio. 9Staining index. 10Vascular 
endothelial growth factor A. 11Vascular endothelial growth factor receptor 2. 12Platelet derived 




Supplementary table 3 Biomarkers in relation to plasma Interleukin 6 signal transducer 
 Plasma Interleukin 6 signal transducer 
 ≤ median 
n(%) 




    
ELISA markers:    
Baseline pIL62   0.55 
  Low 10(44) 13(56)  
  High 12(57) 9(43)  
Baseline pIL6R3   0.08 
  Low 8(36) 14(64)  
  High 15(65) 8(35)  
Change in pIL6 between baseline and week 
12 
  1.00 
  Decrease 3(50) 3(50)  
  Stable/Increase 8(40) 12(60)  
Change in pIL6R between baseline and 
week 12 
  0.37 
  Decrease 1(41) 6(86)  
  Stable/Increase 8(38) 13(62)  
Clinicopathologic markers at baseline:    
Sex   0.07 
  Female 12(71) 5(29)  
  Male 11(39) 17(61)  
Age   0.08 
  ≤ median  8(36) 14(64)  
  > median 15(65) 8(35)  
IMDC4 criteria   0.285 
  Favorable 2(33) 4(67)  
  Intermediate  6(46) 7(54)  
  Poor 12(67) 6(33)  
WHO6 performance status - No. (%)   0.53 
  0 14(47) 16(53)  
  1 9(60) 6(40)  
Hypertension   0.14 
  Yes  9(39 14(61)  
  No 14(64) 8(36)  
s-CRP7   1.00 
  ≤ 10  9(50) 9(50)  
  > 10 14(54) 12(46)  
NLR8 ratio > 3 vs ≤ 3   1.00 
  > 3  13(54) 11(46)  
  ≤ 3 10(59) 7(41)  
Number of disease sites - No. (%)   0.045 
  1 5(56) 4(44)  
  2 2(18) 9(82)  
  ≥3 16(64) 9(36)  
Quality of life at baseline:    
Function scale   0.16 
  Lower 3 quartiles 8(73) 3(27)  
  Upper quartile 14(42) 19(58)  
Symptom scale   0.49 
  Lower 3 quartiles 7(64) 4(36)  
  Upper quartile  15(46) 18(55)  
Immunohistochemistry -tumor expression 
of: 
   
Interleukin 6    1.00 
6 
 
  SI9 = 0-2  10(53) 9(47)  
  SI = 3-9 10(56) 8(44)  
Interleukin 6 receptor α    1.00 
  SI = 1-3  6(40) 6(50)  
  SI = 4-9 14(56) 11(44)  
Jagged 1   0.33 
  SI = 0-2  9(45) 11(55)  
  SI = 3-9 11(65) 6(35)  
VEGFA10    1.00 
  SI = 1-3  4(57) 3(43)  
  SI = 4-9 16(52) 15(48)  
VEGFR211   0.20 
  SI = 0-2  10(67) 5(33)  
  SI = 3-9 10(44) 13(57)  
PDGFRβ12   0.49 
  SI = 0-1  8(57) 6(43)  
  SI = 2-9 8(42) 11(58)  
HSP2713   0.16 
  SI = 1-3  4(33) 8(67)  
  SI = 4-9 16(62) 10(39)  
 
1Fisher’s exact test. 2Plasma interleukin 6. 3Plasma Interleukin 6 receptor 4The International 
Metastatic Renal Cell Carcinoma Database Consortium. 5Pearson Chi-square 6World Health 
Organization 7C-reactive protein. 8Neutrophil/lymphocyte ratio. 9Staining index. 10Vascular 
endothelial growth factor A. 11Vascular endothelial growth factor receptor 2. 12Platelet derived 
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